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Acute myeloid leukemia (AML) is a heterogeneous disease caused by a variety of mutations 16 
in transcription factors, epigenetic regulators and signaling molecules. To determine how 17 
different mutant regulators establish AML subtype-specific transcriptional networks we 18 
performed a comprehensive global analysis of cis-regulatory element activity and interaction, 19 
transcription factor occupancy and gene expression patterns in purified leukemic blast cells. 20 
Here, we focussed on specific sub-groups of patients carrying mutations in genes encoding 21 
transcription factors (RUNX1, CEBPA) and signaling molecules (FTL3-ITD, RAS, NPM1). 22 
Integrated analysis of these data demonstrates that each mutant regulator establishes a 23 
specific transcriptional and signaling network unrelated to normal cells sustaining the 24 
expression of unique sets of genes required for AML growth and maintenance. 25 
  26 
 2
Introduction 27 
 28 
Acute myeloid leukemia (AML) is characterized by blocked myeloid lineage differentiation 29 
and accumulation of leukemic blast cells. AML is a highly heterogeneous disease caused by 30 
different types of mutations affecting signaling pathways as well as transcriptional and 31 
epigenetic regulators1-3. Recurrent mutations include loss of function mutations in 32 
transcription factors (TFs) controlling hematopoietic development, such as RUNX1, GATA2 33 
or C/EBPα4, and gain of function mutations in signaling molecules such as FLT3, KIT, JAK2 34 
and NRAS regulating inducible TFs such as NF-κB, STAT or AP-1 family members5,6,7. The 35 
most common FLT3 mutations are internal tandem duplications (FLT3-ITD), which give rise 36 
to a constitutively active growth factor receptor8,9 and often occur together with 37 
nucleophosmin1 mutations (NPM1). Another major group of mutations alters genes 38 
encoding epigenetic and chromatin regulators10,11. Genes belonging to this class play 39 
widespread roles in development and differentiation by controlling establishment, 40 
maintenance and extinction of lineage-specific gene expression programs. These include 41 
regulators of histone and DNA methylation such as MLL, EZH2, BCOR, TET2, DNMT3A and 42 
IDH1/211-17. In normal cells, all common mutation targets cooperate to control the finely 43 
balanced gene expression changes essential for cell differentiation and lineage commitment.  44 
 TFs interact with defined target gene sequences and recruit epigenetic regulators to 45 
program specific chromatin states and mediate the coordinated activation and de-activation 46 
of cis-regulatory elements driving gene expression18,19. Distal cis-regulatory elements 47 
interact directly with proximal promoter elements, an arrangement that is both dynamic and 48 
robust20,21. From global studies examining a few selected types of AML we know that gene 49 
expression patterns and the epigenetic landscape differ from normal cells22-27. However, how 50 
the disruption of specific TF activity leads to a specific pattern of aberrant chromatin 51 
programming and changes in gene expression in AML is unclear. We do not know at the 52 
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global level which cis-regulatory elements are affected in their activity in different types of 53 
AML, how their activity is altered in patients carrying TF and signaling mutations, how such 54 
differential activity relates to the differentiation block in primary cells of actual patients and 55 
which factors maintain their transcriptional networks.  56 
 In this study we addressed these questions by collecting transcriptome, digital 57 
footprinting and chromatin conformation capture data from purified leukemic blasts from 58 
AML patients with defined transcription factor and signaling molecule mutations with the aim 59 
of defining the components of AML subtype-specific regulatory circuitries. Our study 60 
provides global insights into mutation-specific chromatin programming, and comprises a 61 
comprehensive resource of the transcriptional networks of different AML subtypes, 62 
highlighting pathways required for tumour maintenance 63 
 64 
 65 
Results 66 
AML with different mutant regulators adopt unique chromatin landscapes 67 
In order to examine how specific TF and signaling mutations alter the epigenome of AML, 68 
we purified CD34+ or CD117+ leukemic blast cells from bone marrow or peripheral blood 69 
samples from a cohort of AML patients (Fig 1A). After determining the mutation status by 70 
targeted sequencing and cytogenetics (Table S1), we selected a cohort of patients with 71 
defined mutations in transcription factor, signaling and epigenetic regulator genes. Mutations 72 
included: RUNX1 mutations affecting DNA-binding (D-type) or lacking the trans-activating 73 
domain (T-Type), t(8;21) translocations fusing the DNA binding domain of RUNX1 to the co-74 
repressor ETO, inv(16) which fuses CBFβ to smooth muscle myosin heavy chain 11 75 
(MYH11) protein, independent mutations of both alleles of the CEBPA gene whereby at one 76 
mutation leads to loss of DNA-binding activity28 and FLT3-ITD with or without NPM1 77 
mutations. One of the patients carrying a RUNX1 mutation (RUNX1-T-7) who had Non-78 
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Hodgkin Lymphoma (NHL) was included as an alternative class of patient. To identify AML-79 
specific gene regulatory networks we performed high read depth DNaseI-Seq (Fig.1B) and 80 
RNA-Seq (Fig S1A) on 29 samples comprising seven major groups, and at least one 81 
analysis on 12 additional samples, with mutations such as NRAS, CBL, JAK2, SRFS2, or 82 
inv(3), as defined in Table S1. Samples were compared to CD34+ mobilized peripheral 83 
blood stem cells (PBSCs) from the peripheral blood of two healthy individuals and to cord 84 
blood (CB) CD34+ cells. To provide the community with a data resource, we established an 85 
online database containing multiple data-sets including a genome browser (see Data 86 
Availability). 87 
 Unsupervised clustering revealed that distal DHSs clustered in different groups 88 
according to the class of mutations (Fig 1C). Samples with FLT3-ITD and/or NPM1 89 
mutations represented one major group with sub-clusters for patients with NPM1 mutations 90 
or carrying two FLT3-ITD alleles, but excluding a FLT3-ITD patient carrying a RUNX1 91 
mutation. DHSs from the t(8;21), inv(16) and CEBPA double mutant patients clustered as 92 
discrete groups within a larger group, indicating that these mutations affect similar pathways. 93 
Examples of these patterns can be seen for DHSs in the POU4F1 locus in t(8;21) and 94 
CEBPA-mutated samples, and DHSs in the FOXC1 locus in patients with FLT3-ID or NPM1 95 
mutations (Fig. S1B).  DHSs from patients with RUNX1 mutations were more heterogeneous 96 
and formed a larger cluster together with the PBSCs and the inv(3) patients. The NHL 97 
(RUNX1-T-7) and the NPM1/RAS sample were unrelated to any of the others. We further 98 
validated our findings by including an independently derived published ATAC-Seq data-set 99 
in our analysis25, confirming that mutations in FLT3 underpin one major component of the 100 
clustering (Figure S2A). In contrast, the presence or absence of epigenetic mutations such 101 
as DNMT3A did not influence chromatin accessibility levels (Fig. S2B) or gene expression 102 
(data not shown).  103 
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 Unsupervised clustering analysis of RNA-Seq data from the same patients (Fig S1C, 104 
S2C) revealed strong correlations between mutation-specific accessible chromatin 105 
landscapes and mutation-specific differential gene expression. This was again exemplified at 106 
the POU4F1 and FOXC1 loci (Fig. S1D) where the mRNA patterns correlated well with the 107 
chromatin profiles (Fig. S1B). We identified distinct patterns of expression for specific TF 108 
genes in different AML types (Fig S2D), with, for example a number of homeo-domain gene 109 
family members (HOX, NKX, IRX and PBX families) specifically up-regulated in the FLT3-110 
ITD and NPM1-mutated patients. In summary, our comparative analyses show that aberrant 111 
TFs and chronic signaling impose distinct mutation group-specific programs of chromatin 112 
accessibility and gene expression, irrespective of the presence of other classes of mutations 113 
such as DNMT3A.  114 
 We next investigated, whether the mutation class and its associated DHS pattern 115 
correlated with a block at a specific stage of the differentiation. Here we again used 116 
published ATAC-Seq data25 describing the open chromatin landscape of normal stem and 117 
progenitor cells (Fig 2A). Our DNaseI-Seq data correlated well with these data (Fig S3A and 118 
S3B), whereby CD34+ PBSC sequences clustered with hematopoietic stem cells (HSCs) 119 
and early progenitors but not monocytic cells. When compared to the various types of 120 
progenitor cells, t(8;21), inv(16), CEBPA(x2) and NPM1-mutated AML displayed distal 121 
element patterns most similar to those of normal GMPs, with some differentiation into 122 
monocytes (Fig 2B). In contrast, RUNX1 and FLT3-ITD/NPM1 mutated AML displayed a 123 
spread of lineage-specific patterns with little or no monocytic differentiation (Fig 2B). Gene-124 
set enrichment analysis comparing the gene expression patterns of AML cells with the 125 
various progenitor stages confirmed that the mutation-group specific cistrome was mirrored 126 
by the gene expression pattern (Fig 2C). However, although AML subtypes showed some 127 
characteristics of normal progenitor cells, they still clustered away from normal cells (Fig 128 
S3B). Importantly, our mutation analyses showed no indications for the presence of 129 
 6
confounding major sub-clones in the purified undifferentiated AML cell population, as 130 
mutations were present at close to either a 50% or a 100% allele frequency (Dataset S1).  131 
 132 
AML-specifically active cis-regulatory elements cluster into common and unique 133 
groups  134 
We next examined which active cis-regulatory elements were specific for each AML subtype 135 
and which TF families were responsible for their activation. To this end, we defined the union 136 
of all AML-specific DHSs as compared to CD34+ PBSCs and performed k-mean clustering 137 
to identify unique and common DHSs shared between patients, which identified 20 distinct 138 
DHS clusters (Fig 3A). Less than half of these DHSs were found in any of the Corces et al.25 139 
progenitor data ATAC-Seq sets and the percentage overlap varied substantially between 140 
clusters (range 2 – 40%; Fig. 3C). These data indicated that AML cells did indeed reprogram 141 
their chromatin and adopted a separate identity compared to all stages of normal myeloid 142 
cells. We also verified mutation-specific clustering behaviour of our samples by comparing 143 
them with a recently published AML histone H3K27 acetylation data set containing samples 144 
with FLT3-ITD, RUNX1 and CEBPA double mutations. Mutation-specific cis-regulatory 145 
elements from this study26 largely overlapped with the mutation-specific DHSs identified here 146 
(Fig. S3D). We then defined mutation specific groups of deregulated DHSs that were shared 147 
between the specific members of each of the seven major mutation groups defined in Table 148 
S1 (Figs. S4A and S4B) which were distributed between both the mutation-specific clusters 149 
and the shared clusters (Fig 2B) and were associated with differentially expressed genes 150 
(Dataset S2). As seen above in the clustering analysis, the t(8;21), inv(16), and CEBPA  151 
groups showed similar patterns whereby 914 upregulated DHSs were shared between the 152 
three groups (Fig. S4A). The  FLT3-ITD, FLT3- ITD/NPM1 and NPM1 mutation groups also 153 
showed substantial overlap with 942 shared DHSs, and with only 19% of these DHSs also 154 
included in the 914 ITD/NPM1-specific DHSs. These AML-specific patterns showed little 155 
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similarity to normal myeloid differentiation as the majority of these specific sites were not up-156 
regulated in GMPs relative to PBSCs (Supplementary note SN1B). 157 
 The presence of specific DHSs strongly correlated with the up-regulation of their 158 
nearest genes (Dataset S3), indicating that AML type-specific cis-regulatory elements drive 159 
the expression of AML type-specific genes (Fig S4C) as exemplified by a DHS at POU4F1 160 
(Fig S4D). Fig S4E shows examples of AML-specific up-regulated genes of regulatory 161 
relevance, including those encoding growth factor receptors or TFs which were associated 162 
with the presence of AML type-specific DHSs, in this case NFIX, POU4F1, MEIS1 and 163 
FOXC1 (Dataset S4). The gene expression patterns of such genes were validated using 164 
publicly available data-sets (Fig S5). 165 
 166 
Mutation-specific cis-regulatory elements display specific transcription factor 167 
occupancy patterns 168 
To identify TF motifs responsible for the establishment of the different patterns, we 169 
performed digital footprinting analysis from high-read depth DNaseI-Seq data using our 170 
Wellington algorithm29. We began by creating a curated list of motifs based on several TF 171 
databases (Table S2) since closely related factors typically recognise identical sequences. 172 
We therefore selected single representative motifs for each of the different transcription 173 
factor families, so as to remove redundant motifs bound by multiple factors. Examples of 174 
footprints are depicted for NFI and ETS motifs at the MDFI locus in FLT3-ITD/NPM1-175 
mutated AML (Fig. 4A) and for RUNX, NFAT and C/EBP motifs at the C3AE1 locus in t(8;21) 176 
and CEBPA-mutated AML (Fig. S6A). The majority of AML type-specific DHSs within the 20 177 
AML-specific DHS clusters contained footprints, as exemplified by a DHS at C3AE1 178 
(Fig.S6B). For validation, we compared RUNX motif footprints with publicly available RUNX1 179 
ChIP data from our studies (FLT3-ITD/NPM124, t(8;21)30) and others (inv(16)31) (Fig.S6C). 180 
Between 60% and 85% of footprinted RUNX motifs occurred in regions shown to bind 181 
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RUNX1. Additional motif enrichment analyses of up-and down regulated DHSs are shown in 182 
Supplemental Notes, Fig SN1 - 3. 183 
 We next evaluated occupied motifs for enrichment in any of the AML type-specific 184 
DHSs defined by the 20 DHS clusters (Fig. 4B). This analysis showed that motif occupancy 185 
patterns were highly AML type-specific. For example, the FLT3-ITD/NPM1-specific clusters 186 
5 and 19 are enriched for occupied HOX, PBX, FOX/E-box and NFI motifs. Occupancy 187 
correlated with up-regulation of multiple homeo-domain genes together with FOXC1 and 188 
NFIX (Fig S2C). We have previously shown that AP-1 is a crucial mediator of FLT3-ITD 189 
signaling24. Occupied AP-1 motifs are enriched in multiple clusters (01, 05, 07, 12, 13, 18, 190 
19), many of which come from AML with signaling mutations. The same is true for NF-κB 191 
motifs which are enriched in clusters 01, 03, 06, and 08 which are shared amongst different 192 
AML groups. NF-κB and AP-1 factors are mediators of MAP kinase signaling which points to 193 
a wide-spread and specific activation of this signaling pathway not just in FLT3-ITD AML24, 194 
but in other AML types. Composite ETS/E-box motifs are occupied in clusters 02, 17 and 20 195 
(associated with the CBF/CEBPA groups), and also in clusters 03, 11 and 14. Finally, we 196 
observed significant occupancy of the motif for POU4F1 in clusters 02 and 20 containing 197 
samples from patients carrying the t(8;21) and CEBPA double mutations, but nowhere else 198 
(Fig4B). POU4F1 has been shown to be aberrantly expressed in t(8;21) cells32, but has so 199 
far not been linked to CEBPA double mutations. A similar differential occupancy picture was 200 
seen when footprints were clustered according to mutation-specific groups of DHSs (Fig. 201 
S6D). Inspection of motif occupancy of C/EBP motifs in AMLs where both alleles of CEBPA 202 
are mutated showed little, if any, reduction in overall motif occupancy, indicating a 203 
compensatory action of other C/EBP family members (Fig S6D) which are expressed in 204 
these cells (Dataset S4). This analysis connects the AML type-specific occupancy of the 205 
motifs to the AML subtype-specific expression of defined sets of TFs and demonstrates that 206 
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their expression is of functional relevance for the programming of chromatin at their target 207 
genes.  208 
 To examine the position of transcription factor occupancy patterns within the 209 
hematopoietic hierarchy, we correlated the presence of footprints specific for the different 210 
AML-subtypes with accessible chromatin regions present in precursor cells (Fig 4C) 25. This 211 
analysis revealed unique factor occupancy patterns of AML cells compared to normal 212 
progenitor cell types. For example, HOX motifs within open chromatin regions observed in 213 
HSCs, MPPs and MEPs are occupied in the FLT3-ITD/NPM1 and RUNX1 groups, but not in 214 
the t(8;21) group, confirming the early block in differentiation (Fig 2B). Many of the samples, 215 
including NPM1, FLT3-ITD/NPM1 and t(8;21) cells, also displayed high AP-1 motif 216 
occupancy which is normally only seen in monocytes. POU4F1 is expressed in HSCs, 217 
MPPs, MEPs and in CLPs25 and its binding motifs are occupied in t(8;21) and CEBPA 218 
double mutant cells, yet these AML cells also show strong occupancy of C/EBP motifs, 219 
which is normally a hallmark of GMPs and Monocytes.  220 
 In summary, our high-resolution digital footprinting analysis shows (i) that each AML 221 
subtype employs a different combination of factors binding to elements shared with different 222 
types of precursor cells and that (ii) lineage unrelated expressed TFs such as FOXC1, NFIX 223 
and POU4F1 participate in such cooperation. 224 
 225 
AML type-specific cis-regulatory elements show differential intra-chromosomal 226 
interactions mediated by shared and specifically expressed transcription factors 227 
The construction of gene regulatory networks requires the linking of cis-regulatory elements 228 
to their respective promoter33. We therefore examined whether the differential activity of cis-229 
regulatory elements in different AML sub-types resulted in the formation of alternate cis-230 
element interactions, and which TF families mediated such interactions. To this end we 231 
analysed cells from relapse patient sample t(8;21)-1R (Table S1), which maintained a gene 232 
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regulation network similar to the presentation sample t(8;21)-1 (Figs. 1C, S1C and S7A),  233 
and a patient carrying a FLT3-ITD/NPM1 mutation (ITD/NPM1-2, Table S1) using promoter-234 
capture chromosomal structure analysis (CHi-C) and compared these data to a dataset 235 
derived from human CD34+ cells34. Most interactions occurred intra-chromosomally and did 236 
not differ at the global level (Fig. S7B). Fig 5A shows interactions across a segment of 237 
chromosome 2, projected on the DHS pattern, demonstrating the organization of this this 238 
region into topologically associated domains (TADs) that are separated by regions devoid of 239 
DHSs. This higher-level structure was unaffected by the type of AML.  240 
 Intra-chromosomal interactions driving gene expression are mediated by 241 
transcription factor complexes binding to cis-regulatory elements which exist as DHS. The 242 
proportion of DHSs involved in AML type-specific interactions varied between the DHS-243 
clusters (Fig 3A, Fig S7C). Moreover, ~40% of all promoters showing differential interactions 244 
were associated with expressed genes (Fig S7D,E). Fig S7F shows a direct comparison 245 
between the data from the two patients and demonstrates that differential interactions (i) 246 
correlated with a differential DHS pattern and that (ii) this difference led to the expression of 247 
a differential set of genes with different GO terms (Dataset S5). Fig S7G shows an example 248 
of differential interactions within the KLF2 gene which is differentially expressed between 249 
FLT3-ITD and t(8;21) and CD34+ cells. 250 
 On average 80% of all DHSs mapped in the t(8;21) AML, the FLT3-ITD AML and the 251 
CD34+ cells participated in interactions (Fig S7H). An an average of 17% of interactions 252 
were specific for each AML-type and not found in CD34+ PBSCs (Fig S7I), whereby half of 253 
these were unique to the type of AML (Fig S7J). To identify the TF families involved in 254 
regulating differential interactions we determined the proportions of enriched occupied motifs 255 
in the DHSs underlying interactions (Fig S7K). These analyses revealed (i) that 256 
hematopoietic TFs such as RUNX, ETS and C/EBP family members participated in 257 
differential interactions in both AML types, together with the ubiquitously expressed inducible 258 
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AP-1 factor family and the normally invariantly binding CTCF factor and (ii) that AML 259 
subtype-specifically expressed TFs participated in such interactions as well. In the FLT3-ITD 260 
AMLs this included HOX proteins and factors occupying FOX/E-box motifs. In the t(8;21) 261 
AMLs this included NF-κB and proteins binding to FOXO motifs as well as POU4F1, with 262 
some motifs being differentially occupied in the same DHS cluster.   263 
 264 
Differential interactions drive AML subtype-specific expression of signaling genes but 265 
the majority of interactions are shared 266 
 In order to integrate differential interactions between promoters and DHSs, digital 267 
footprinting data and gene expression data, we assigned the respective DHSs to the 268 
promoter they interact with for the two patient classes as described in Fig 5B. We next used 269 
these interactions to link DHSs to their respective promoters for AML type-specifically 270 
expressed genes across all FLT3-ITD/NPM1 and t(8;21) patients as compared to CD34+ 271 
PBSCs. This analysis revealed that the vast majority of DHS underlying interactions 272 
between the three data-sets and those of individual patients were shared with an average 273 
level of more than 80% overlap (Fig S8A) confirming earlier observations that the global 274 
transcriptional network of related cells is also highly related35,36. Sub-type-specific DHSs 275 
participating in interactions clustered within their patient group, and related groups, but not 276 
with unrelated groups (Fig S8B), confirming that the two patients were representative for 277 
those groups. For both the FLT3-ITD/NPM1 and the t(8;21) sample the nearest promoter 278 
accounted for 65-74% of AML type-specific interactions driving the expression of genes that 279 
are up-regulated compared to CD34+ cells (Figure 5C). Similar results were seen for each of 280 
the 20 DHS clusters (Fig. S8C). 281 
 GO-term and KEGG-pathway analysis of expressed genes in the two types of AML 282 
(Fig 5D-G) revealed an AML type-specific core signature of genes being driven by specific 283 
cis-regulatory elements (for an extended gene list see Dataset S5). For both AML samples 284 
 12
these included genes involved in regulating pro-inflammatory pathways such as cytokine 285 
receptor signaling and NF-κB signaling. FLT3-ITD cells also displayed an activated MAP 286 
Kinase signaling signature whereas the t(8;21) signature also included RAP, RAS, PI3K and 287 
FOXO signaling genes. Significantly, FOXO1 is already known to be part of the t(8;21) pre-288 
leukemic maintenance program37. Importantly, more that 50% of all genes within these 289 
pathways were targets of RUNX1-ETO (Figure 5H)30 linking them to the actual driver 290 
mutation. A similar percentage of the genes within the FLT3-ITD/NPM1 core pathway are 291 
bound by RUNX1 (Fig 5H) which is up-regulated in FLT3-ITD24 (Dataset S5). This included a 292 
number of growth factor receptor genes such as the normally T-cell specifically expressed 293 
IL-2 receptor alpha chain which is specifically up-regulated in FLT3-ITD/NPM1 patients.  294 
 We noticed that ~83% of the DHSs which were involved in significant interactions in 295 
each of the 3 samples (Fig S8D). We therefore merged all three CHi-C data-sets (Fig S8D) 296 
to use this data to assign the DHS from the 20 clusters (Fig 3A) to their respective 297 
promoters. The remaining 17% of DHS were assigned to the nearest promoter. Genes 298 
associated with the DHS with confirmed interactions are listed in Dataset S6. GO-term and 299 
KEGG-pathway analysis of such genes again showed activation of genes connected with 300 
signaling processes such as an inflammatory response, regulation of MAPK activity and 301 
cytokine regulation in all types of AML. 302 
 303 
Different types of AML are maintained by different transcription factor networks 304 
Constitutive and inducible transcription factors form regulatory circuitries and networks by 305 
interacting with their own/or other regulatory genes35. Cancer cells are capable of 306 
maintaining a stable regulatory network over extended periods of time, implying that the 307 
expression of each member of such a network is tightly controlled and remains in balance. 308 
Consequently, perturbation of the network components maintaining this balance may 309 
destabilize leukemic cells thus offering novel therapeutic options. We therefore combined 310 
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footprinting, TF gene expression and where possible, CHi-C data to construct transcription 311 
factor networks in normal CD34+ cells and the different AML subtypes by linking occupied 312 
binding motifs on TF genes to specific TF families. The full network structure for each cell 313 
type without filtering can be studied in detail via the weblink (http://bioinformatics-314 
bham.co.uk/tfinaml/). Comparison between the different AML subtypes and normal CD34+ 315 
cells identified interactions between TF sets that were either shared between AMLs and 316 
CD34+ cells (Fig. S9) or were specific for each subtype (Fig. 6). These analyses suggested 317 
that the AP-1 family network, which is known to integrate multiple MAPK signalling 318 
pathways, is of central relevance for leukemic maintenance in all AML subtypes (Fig 6 B-G). 319 
Interestingly, in each case these networks reveal tight links between AP-1 and KLF family 320 
members that form another node of general relevance in each AML. POU4F1 and HLH 321 
family factors that recognising MYC/MAX type E-boxes formed prominent nodes in t(8;21) 322 
AML only, while HOX proteins, FOXC1, NFIX and the MAF family were exclusively 323 
highlighted in FLT3-ITD and NPM1mut-associated AML. Specific nodes and edges were 324 
also part of the normal precursor program (Fig S9). For example the link between the C/EBP 325 
family and NFIL3 was shared between the FLT3-ITD/NPM1 cells (Fig 6F) and CD34+ 326 
PBSCs (Fig S9F). A detailed discussion of the different network structures and the role of 327 
different TF families with more examples can be found in Supplemental Note 5. 328 
 329 
Network analysis identifies transcription factors contributing to AML propagation  330 
We next used our network analyses to guide experiments validating the important role of 331 
TFs forming network nodes that were either widely employed in AML, or which were AML 332 
type-specific. To this end, we transduced three different AML cell lines and primary FLT3-333 
ITD AML cells with lentiviral vectors coding shRNAs targeting POU4F1 (specific for 334 
t(8;21)),or targeting NFIX or FOXC1 (specific for FLT3-ITD), as well as control shRNAs. 335 
NFIX is known to play a role in myeloid lineage specification38 but has not been linked to 336 
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specific mutation types. FOXC1 is an oncogene in its own right39 and overexpression is 337 
observed in AMLs with FLT3-ITD mutations24. However, NFIX and FOXC1 have not yet 338 
been directly linked to the maintenance of the FLT3-ITD AML-phenotype. We applied two 339 
distinct shRNA constructs per TF gene with all of them significantly reducing the 340 
corresponding TF transcript and protein levels in FLT3-ITD and t(8;21) cell lines (Fig S10A-341 
F). Knockdown of POU4F1 (Figs. S10 A and D) significantly inhibited the proliferation of 342 
t(8;21)-positive Kasumi-1 cells (Figs. 7A and S10G) in agreement with our previous 343 
findings32. Similarly, expression of NFIX shRNAs efficiently suppressed NFIX expression 344 
(Figs. S10B and E) and significantly impaired the proliferation of FLT3-ITD-positive MV4-11, 345 
but not FLT3-ITD-negative Kasumi-1 cells (Figs. 7B,C, S10H,I). We next tested the effect of 346 
transduction of shRNA constructs targeting these genes on the colony forming ability of 347 
patient CD34+ cells carrying the FLT3-ITD/NPM1 mutations as well as on sorted CD34+ 348 
PBSCs. Importantly, both NFIX and FOXC1 shRNA constructs reduced the colony forming 349 
ability of patient AML cells carrying the FLT3-ITD/NPM1 mutations, but not that of normal 350 
CD34+ HSP cells (Figs. 7D, E). 351 
 In addition to subtype-specific TFs such as POU4F1 or NFIX, our network analysis 352 
suggested that the AP-1 TF family is of general significance for all AML subtypes examined. 353 
AP-1 is a heterodimer formed by members of the FOS, ATF, JUN and JDP families of 354 
transcription factors and, consequently, challenging to target by defined RNAi approaches. 355 
In order to interfere with the binding of all AP-1 family members, we introduced an inducible 356 
version of a dominant negative FOS (dnFOS) protein40,41. Doxycyclin-mediated induction of 357 
dnFOS significantly inhibited proliferation of both t(8;21)-positive Kasumi-1 cells and FLT3-358 
ITD expressing MV4-11 cell lines as compared to non-induced controls (Figs. 7F, G, S10J, 359 
K). Moreover, transduction of primary CD34+ FLT3-ITD cells with a lentivirus encoding a 360 
constitutively expressed dnFOS reduced the colony forming ability of MV4-11 FLT3-ITD cells 361 
but not of CD34+ HPSCs (Figs. 7H, I, S10L). Finally, we examined the significance of AP-1 362 
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for leukaemia propagation in vivo. To that end, we transplanted either Kasumi-1 or MV4-11 363 
cells expressing a doxycycline-inducible dnFOS into immunodeficient RG mice followed by 364 
randomization into a doxycycline and untreated arm. In the case of Kasumi-1 365 
transplantation, 6 out of 7 animals of the control group, but only 2 animals of doxycyclin-366 
treated group developed granulosarcomas (Fig. 7J). Importantly, neither of the latter two 367 
tumours expressed dnFOS after DOX treatment (data not shown), further suggesting that 368 
induction of dnFOS was incompatible with tumour formation. Similarly, doxycycline treatment 369 
of mice transplanted with FLT3-ITD MV4-11 cells that harbored the dnFOS transgene 370 
inhibited the development of leukemia while all untreated mice rapidly developed tumours 371 
and had to be sacrificed (Fig. 7K). Taken together, these findings demonstrate the 372 
significance of AP-1 for several AML subtypes and emphasize the potential of transcriptional 373 
network analyses to predict TFs crucial for malignant propagation. 374 
 375 
Discussion 376 
In this study we define how aberrantly expressed TFs and signaling molecules shape the 377 
epigenetic landscape of different sub-types of primary AML. We show (i) that it is possible to 378 
use high-quality DNaseI footprinting analysis of purified AML blast cells to identify AML 379 
subtype specific TF networks, (ii) that such TF networks allow us to infer a dependency on 380 
specific factors for leukemic growth and (iii) that the global activation of signaling pathways 381 
in multiple types of AML parallels a growth dependency on AP-1 activity. This 382 
comprehensive integrative comparison of gene expression patterns, chromatin accessibility 383 
and TF occupancy of primary AML reveals a strong connection between leukemic classifier 384 
mutations and networks of TFs and signaling components. Moreover, mapping of cis-385 
element promoter interactions by CHiC enabled assigning the majority of genes of all 386 
analysed subtypes to their correct promoter. It has long been known that different types of 387 
AML can be characterised by their gene expression and methylation patterns42,43 suggesting 388 
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the existence of specific gene regulatory networks. However, our work now defines these 389 
networks in detail, and convincingly proves that leukemic drivers determine the regulatory 390 
phenotype by establishing and maintaining gene regulatory and signaling networks distinct 391 
from normal cells. Networks consist of shared and specific components and even involve 392 
regulators normally not expressed in myeloid cells, such as such as FOXC1 or POU4F1. 393 
Our validation experiments show that induced and aberrantly expressed TFs are not just 394 
bystanders, but are important for network maintenance and leukemic growth, thus 395 
harbouring novel therapeutic opportunities for targeted treatment. 396 
 A clinically relevant novel finding from our study is that CEBPA double mutant AML is 397 
epigenetically highly related to t(8;21) AML. The t(8;21) is driven by a single aberrant TF 398 
(RUNX1-ETO) which is sufficient to establish a pre-leukemic state and whose mechanism of 399 
action has been under scrutiny for many years. The most likely reason for this epigenetic 400 
congruence between t(8;21) and CEBPA double mutant AML is that both mutations target a 401 
common key control point of myeloid differentiation. RUNX1-ETO represses the CEBPA 402 
gene while C/EBPα is required for the differentiation response of t(8;21) cells to RUNX1-403 
ETO knock-down22. Consequently, the two types of AML share a number of pathways, as 404 
exemplified by the expression of POU4F1, which could be translated into common 405 
therapeutic strategies. 406 
 The full set of target genes of RUNX1-ETO in t(8;21) is known and the t(8;21) 407 
specific epigenome and TF binding pattern has been extensively characterized44. A number 408 
of target genes relevant for the maintenance or establishment of the leukemogenic state 409 
have already been identified, including FOXO1, UBASH3B, POU4F1, and LAT2 together 410 
with the members of the RUNX1-ETO complex 22,32,37,45-47. Our current comparative study 411 
has validated these targets, highlighting the power of our methodology and has identified 412 
multiple new network components. However, for the other types of AML, in particular for the 413 
FLT3-ITD there had been insufficient knowledge of which genes and TFs are primarily 414 
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responsible for directing the AML type-specific gene regulatory networks. Here, we identified 415 
a number of signaling and transcriptional components distinguishing FLT3-ITD from normal 416 
blasts and from other types of AML comprising a rich resource for combination therapy 417 
approaches. We examined the contribution to leukemic growth for two genes with AML type-418 
specific activity (NFIX and FOXC1) and showed that in every case their elimination resulted 419 
in a growth reduction in AML but not normal cells, yet again confirming that each type of 420 
AML stabilises a specific transcriptional network required for survival.  421 
 The AP-1 factor family has been known to play an important role in many types of 422 
tumours 48 and our study shows that it is also of major importance for different types of AML.  423 
FLT3-ITD MV4-11 cells have abundant levels of nuclear AP-1, and FLT3-ITD target genes 424 
such as CCNA1 are suppressed by MAP kinase inhibitors in these cells24. We have recently 425 
shown that JUN scores highly in a siRNA dropout screen examining the requirements for 426 
tumour development in t(8;21) AML (Martinez-Soria et al., in press). Moreover, FOS plays 427 
an important role in the resistance against BCR-ABL inhibition in CML by activating 428 
compensatory signaling pathways49. Since several growth factor and stress signal cascades 429 
feed into AP-1, a targeted inhibition of all AP-1 binding may be less likely to lead to 430 
resistance by rewiring of signalling pathways. 431 
 The classical picture of two-step leukemogenesis states that in AML a mutation 432 
altering a differentiation trajectory cooperates with signaling mutations directing leukemic 433 
growth10,11. Mutations in TFs which program chromatin directly, and epigenetic regulators 434 
such as DNMT3A and TET2 which set up a specific global epigenetic landscape upon which 435 
TFs act, fall into the first category while FLT3-ITD falls into the second. However, these 436 
distinctions are now becoming blurred as from the viewpoint of the regulation of gene 437 
expression, growth factor receptors elicit a strong influence on transcriptional activity via the 438 
action of inducible TFs. Moreover, they play a dominant role in driving the differentiation 439 
trajectory as their binding patterns, as exemplified by AP-1 family members, show an AML 440 
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sub-type specific occupancy signature that is uninfluenced by the presence or absence of 441 
epigenetic regulator mutations (in this case DNMT3A)24. This is not to say that mutations in 442 
such genes do not influence the developmental trajectory of AML and clinical outcomes, as 443 
shown in CBF AML50 since AML cells with such mutations acquire an altered DNA 444 
methylation landscape that is likely to influence TF binding51. However, our data show that 445 
the leukemic phenotype and self-renewal in different types of AML defined by differentially 446 
activating a multitude of different and often lineage-unrelated signaling pathways and by 447 
expressing lineage-unrelated TFs. From the viewpoint of finding therapeutic targets, 448 
identifying such mutation-specific pathways will offer to eliminate their specific maintenance 449 
program by targeting multiple pathways simultaneously. Our study provides a first step 450 
towards this goal.  451 
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Methods  452 
 453 
Patient samples and PBSC cell processing 454 
Human tissue was obtained with the required ethical approval from the NHS National 455 
Research Ethics Committee. AML and PBSC samples used in this study were either surplus 456 
diagnostic samples, or were fresh samples obtained with specific consent from the patients. 457 
AML samples were obtained from either (i) the Haematological Malignancy Diagnostic 458 
Service (St James’s Hospital, Leeds, UK, (ii) the Centre for Clinical Haematology, Queen 459 
Elizabeth Hospital Birmingham, Birmingham, UK, (iii) the West Midlands Regional Genetics 460 
Laboratory, Birmingham Women’s NHS Foundation Trust, Birmingham, UK, or from iv) 461 
Erasmus University Medical Center, Rotterdam, The Netherlands. Mononuclear cells were 462 
purified on the same day that they were received, and in most cases also directly further 463 
purified using either CD34 or CD117 (KIT) magnetic antibodies, as previously described 24. 464 
For some samples with greater than 92% blast cells the column purification was not 465 
performed. Mobilized PBSCs were provided by NHS BT, Leeds, and NHS BT, Birmingham. 466 
Mutation detection 467 
Mutated genes identified in each patient are summarized in Supplementary Table 1, 468 
together with the age, gender and white blood cell count for each patient.  Mutations were 469 
identified by one of two different methods. The first batch of patients were assayed by 470 
targeted exon sequencing of 55 cancer-associated genes using 1212 pairs of previously 471 
defined PCR primers 24 for amplification using a RainDance Technologies platform. The 472 
mutation sequence data from this screen was analyzed using algorithms to detect either (i) 473 
nucleotide variants using the Genome Analysis Toolkit (GATK) 52 or insertions and deletions 474 
using Pindel 52. Mutations were also screened against the COSMIC database of previously 475 
observed mutations (http://cancer.sanger.ac.uk/cosmic/). Subsequent samples were 476 
assayed using the Illumina Trusight myeloid panel of primers and processed by approaches 477 
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similar to those used for the first batch. All identified mutations are listed in Table S1. Some 478 
of these patients were also included in a previous publication from our laboratory, using 479 
different patients identification codes 24 to those used in the current study. 480 
Cell lines 481 
Cell lines were cultured in an incubator at 370C in GIBCOTM 1640 RPMI + GlutamaxTM 482 
medium supplemented with 10% heat inactivated fetal calf serum (GIBCO), 100 U/ml 483 
Penicillin, 100 mg/ml Streptomycin. 484 
Growth curve measurements  485 
250000 MV4-11 or Kasumi-1 cells were cultured in RPMI supplemented with 10 % fetal calf 486 
serum, 2mM L-Glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin. Cells were 487 
counted with Trypan Blue exclusion and split every 3 days to maintain them in the log phase 488 
of growth. For the inducible dnFOS, cells were counted and split every 2 days and 1.5 µg/ml 489 
of doxycycline was added. 490 
Co-culture of Primary Cells with MS-5 feeders 491 
Primary cells were maintained in co-culture with MS-5 cells 53 Briefly, cells were cultured in 492 
LTC medium (α-minimum essential medium (Lonza) supplemented with heat-inactivated 493 
12.5% fetal calf serum (Gibco), heat-inactivated 12.5% horse serum (Gibco), penicillin and 494 
streptomycin, 200 mM glutamine, 57.2 μM β-mercaptoethanol (Sigma) and 1 μM 495 
hydrocortisone; (Sigma) supplemented with 20 ng/ml IL-3, granulocyte colony-stimulating 496 
factor (G-CSF) and thrombopoietin (TPO) in flasks pre-coated with MS-5 cells. 497 
Lentiviral transduction and shRNA treatment  498 
LEGO-iG-shRNA were generated by cloning shRNAs with the target sequences described 499 
below into the LEGO-iG vector54. LEGO-iG-dnFOS was generated by cloning the dnFOS 500 
insert, originally generated by Charles Vinson (National Cancer Institute, Bethesda, USA 40 501 
into the LEGO-iG backbone. Inducible dnFOS was cloned into a pENTR backbone and then 502 
using Gateway Cloning to insert that into the Tet-on plasmid pCW57.1 (David Root, 503 
 21
Addgene plasmid #41393). Backbone vectors LEGO-iG and Inducible dnFOS then used to 504 
generate lentiviral particles using packaging and envelope genes on four separate plasmids: 505 
TAT, REV, GAG/POL and VSV-G55. 506 
shRNA Target sequences: shFOXC1_B GTCACAGAGGATCGGCTTGAA; shFOXC1_C507 
 GCCGCACCATAGCCAGGGCTT; shNFIX_B: GGAATCCGGACAATCAGAT; 508 
shNFIX_C GCAGTCTCAGTCCTGGTTCCT; shPOU4F1_C509 
 GCCGAGAAACTGGACCTCAAA;  shPOU4F1: GCCGATTAACAAGACTGAAAT; 510 
shMM GCGCGATAGCGCTAATAATTT 511 
For virus production, 293T Human Embryonic Kidney cells were cultured in Dulbecco’s 512 
Modified Eagle Medium supplemented with 10 % fetal calf serum, 2mM L-Glutamine, 100 513 
U/ml penicillin, 100 mg/ml streptomycin and 0.11 mg/ml Sodium pyruvate; and were seeded 514 
to achieve 70-80% confluency at time of transfection. HEK293T cells were transfected using 515 
the calcium phosphate co-precipitation of the five-plasmids (LEGO-iG with TAT, REV, 516 
GAG/POL and VSV-G) at a mass ratio of 24 μg : 1.2 μg : 1.2 μg : 1.2 μg : 2.4 μg per 150 517 
mm diameter plate of cells. Viral supernatant was harvested after 24 h and subsequently 518 
every 12 h for 36 h prior to concentration with Centricon Plus 70 100 kDa filter (Millipore, 519 
USA), using the manufacturer’s instructions. Concentrated viral particles were stored at 4 °C 520 
prior to lentiviral transduction. Cell lines were transduced with concentrated virus in the 521 
presence of 8 μg/ml polybrene by spinoculation at 1500 xG for 50 min. After 12 – 16 h 522 
incubation at 37 °C viral media was exchanged for fresh media. Cell sorting by FACS was 523 
performed to isolate GFP+ cells 3 days after transduction. 524 
Primary cell samples were defrosted 24 h prior to transduction and co-cultured with MS-5 525 
feeder cells in LTC medium. 6 well non-tissue culture treated plates were coated with 24 526 
μg/ml retronectin (Takara Clontech) for 2 h prior to blocking with 2% BSA PBS for 30 min. 527 
The blocking buffer was washed off with HBSS (Gibco) containing 2.5% HEPES. 1 ml viral 528 
concentrate was applied to the retronectin coated plate by centrifugation at 2000 xG for 45 529 
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minutes, after which the concentrated viral supernatant was refreshed and the centrifugation 530 
repeated. Primary cells suspended to a concentration of 1 x 106 cells/ml in the remaining 531 
viral supernatant; supplemented with 20 ng/ul G-CSF, IL-3, TPO and 8 μg/ml polybrene, 532 
were then added to the plate and transduced by spinoculation at 1500 xG for 50 min. After 533 
12 – 16 h incubation at 37 °C viral media was exchanged for fresh media. Cell sorting by 534 
FACS was performed to isolate GFP+ cells 3 days after transduction. 535 
Colony Formation Assays of Primary Cells 536 
Colony formation assays were performed on sorted cells by seeding at 2500 cells/ml in 537 
Methocult Express (Stem Cell Technologies). After 14 days colonies were counted.  538 
Animal experiments 539 
Immunodeficient Rag2−/−Il2rγ−/−129×Balb/c (RG) mice were housed in the Comparative 540 
Biology Centre (Newcastle University) under specific pathogen free conditions. All animal 541 
work was conducted in accordance with Home Office Project License PPL60/4552 by 542 
researchers who had completed approved Home Office training and held current Personal 543 
Licenses under the Animals (Scientific Procedures) Act 1986. Kasumi-1 pCW57.1-dnFOS 544 
cells were intrahepatically injected into 14 newborn (2 days old) RG mice at a cell dose of 545 
2.5x105 cells/mouse as described previously (Martinez Soria et al., 2009). Twelve days later, 546 
mice were randomized into two treatment groups, one given doxycycline 50 mg/kg three 547 
times per week intraperitoneally in an unblended fashion till the experimental endpoint. MV4-548 
11 pCW57.1-dnFOS cells were intrafemorally injected into RG mice at a cell dose of 5x105 549 
cells/mouse followed by randomization into two groups. For the dox group doxycycline was 550 
added at a concentration of 2 mg/ml for the initial 3 days and at 0.2 mg/ml subsequently to 551 
drinking water containing 2% sucrose. Controls were given water containing 2% sucrose. 552 
Animals were humanely killed upon clinical signs of illness or at defined experimental 553 
endpoints. 554 
RT- qPCR 555 
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RNA was extracted using the Machery-Nagel Nucleospin kit. 1μg RNA was used to make 556 
cDNA with 0.5μg OligoDT primer, Murine Moloney Reverse Transcriptase and RNase 557 
Inhibitor (Promega, USA) according to manufacturer’s protocol.  RT-PCR was performed 558 
using Sybr Green mix (Applied Biosystems, UK), at 2x dilution.  Primers were used at 559 
100nM concentration. A 7900HT system (Applied Biosystems, UK) was used to perform 560 
qPCR. Analyses were performed in technical duplicates using a standard curve derived from 561 
the untreated cell line. 562 
Western Blotting 563 
Protein lysates from cell lines were analysed by Western blot. Relevant primary antibodies 564 
against FOXC1 (Cell Signaling Technology - #8758) , NFIX (Invitrogen - #PA5-31234), 565 
POU4F1 (Santa Cruz Biotechnology – sc-8426) were used to detect target genes and 566 
GAPDH (mouse αGAPDH – Abcam – ab8245; rabbit αGAPDH – Cell Signaling Technology 567 
– 2118L) was used as a housekeeping gene. Secondary antibodies mouse anti-rabbit HRP 568 
(Rockland – 18-8816-31) and goat anti-mouse HRP (Jackson ImmunoResearch – 115-035-569 
062) enabled detection and quantifications by densitometry using Imagelab software and a 570 
GelDoc imager.  571 
RNA-Seq library preparation 572 
RNA was extracted and analyzed from purified AML cells as previously described 23  573 
DNaseI-Seq  574 
DNaseI digestions of permeabilized cells were performed as previously described56. Briefly, 575 
live cells were added directly to a solution of DNaseI (DPFF, Worthington) in dilute Nonidet 576 
P40, digested for 3 min at 22oC, and the reactions then terminated by addition of SDS to 577 
0.5%. DNaseI was typically used in the range of 2-6 μg/ml using a final 1.5 x 107 cells/ml. 578 
DNaseI-Seq libraries were then prepared and validated essentially as previously described 579 
30. Libraries were run on Illumina sequencers. 580 
Promoter capture HiC (CHi-C) from patient AML blasts 581 
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AML cells from patient peripheral blood were first purified by density gradient centrifugation 582 
(Lymphoprep™) and then using CD34 antibody coupled beads. 5× 107 t(8;21) blasts (patient 583 
t(8;21)-1R) and FLT3-ITD/NPM1 blasts (patient ITD/NPM1-2) were fixed in 37 ml of RPMI-584 
1640 supplemented with 15% FBS and 2% formaldehyde for 10 minutes at room 585 
temperature. 6 ml of 1M glycine (0.125 M final concentration) was added to quench the 586 
reaction and cells were incubated at room temperature for 5 min, followed by 15 minutes on 587 
ice before pelleting the cells at 4 °C and washing them in ice cold PBS. Each sample was 588 
flash frozen in liquid nitrogen, and stored at −80 °C. Cells were lysed in a tight dounce 589 
homogeniser (ten cycles) with 3ml of cold lysis buffer (10 mM Tris-HCl pH 8, 10 mM NaCl, 590 
0.2% Igepal CA-630, one tablet protease inhibitor cocktail (Roche complete, EDTA-free, 591 
11873580001)). Cells were left on ice for five minutes then homogenised another ten times. 592 
The lysed cells, in 3 ml lysis buffer, were added to 47ml of lysis buffer and incubated on ice 593 
for 30 minutes with occasional mixing. Chromatin was pelleted and resuspended in 1ml of 594 
1.25x NEBuffer 2 and split into four. Each sample was then pelleted at 1000 rpm and 595 
resuspended in 358 µl of 1.25x NEBuffer 2. 11 µl 10% SDS was added and each tube was 596 
incubated at 37°C for 60 minutes, rotating at 950 rpm. Samples were mixed by pipetting up 597 
and down every 15 minutes. SDS was quenched with 75µl 10% Triton X-100 and incubated 598 
at 37˚C for 60 minutes. HindIII digestion, biotinylation, ligation, crosslink reversal, promoter 599 
capture and library preparation was performed exactly as described in34.  600 
 601 
Bioinformatics analyses 602 
DNaseI-Seq  data analysis 603 
Alignment: DNaseI-seq sequences from all experiments were mapped onto the reference 604 
human genome version hg38, with Bowtie version 2.3.157 using default parameters.  Low 605 
quality reads were trimmed prior to the alignment and the quality control (QC) statistics for 606 
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the samples were obtained using FastQC tools. Reads that were aligned to unique 607 
chromosomal positions were retained. 608 
Peak calling. DNaseI Hypersensitive Sites (DHSs) were called with MACS2 using callpeak 609 
function (nomodel, call-summits and q= 0.005 parameters)58.  DHSs were allocated to genes 610 
and to the gene promoter if it was within 2kb of the gene transcription start site (TSS), and 611 
as distal otherwise. Overlaps between DHSs peaks were defined by requiring the summits of 612 
two peaks to lie within +/-200 bp. 613 
DNaseI-Seq peak set definition: To define a common set of coordinates covering all of the 614 
significant distal DHSs investigated in this study, we merged all of the individual DNaseI-Seq 615 
reads for all of the AML samples assayed by DNaseI-Seq. This data set was then used to 616 
define the peak summits of 128,864 distal peaks, excluding promoters, which were detected 617 
in the merged data. This approach was designed to maximize the precision and sensitivity of 618 
the peak detection, allowing us to generate a single set of peak coordinates that (i) included 619 
all the regions where peaks might be found, thereby reducing the level of false negatives, 620 
and  (ii) greatly diminished the number of false positives. The DNA read counts were then 621 
determined for 400 bp windows centered on each peak for each AML sample and for the 622 
PBSC samples. To account for the different number of reads in each of the samples; the 623 
read counts were initially normalized for total read depth using DEseq2 59. Because most of 624 
our individual DNaseI-Seq data sets encompassed in the range of 25,000 to 40,000 625 
significant distal DHSs, we further normalized the values obtained on the basis of the 626 
midpoint (12.5 percentile) of the top 25% of peaks (32,216 peaks).  627 
Mutation-specific DNaseI-Seq peak set definition: We determined the average log2 628 
values for 7 distinct subsets of AMLs that carried the same specific mutations in key 629 
regulators, and which shared similar patterns of DHSs based on the DHS clustering analysis. 630 
The samples included in each group are color-coded and listed in order in Table S1 for AML 631 
samples with the following mutations: (i) 3 samples with FLT3-ITD but not NPM1 (#1 to 3), (ii) 632 
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6 samples with FLT3-ITD and NPM1 (# 1 to 6), (iii) 2 samples with NPM1 but not FLT3-ITD 633 
(# 1 and 2), (iv) 4 samples with t(8;21) (1 to 4), (v) 3 samples with inv(16) (# 1 to 3); (vi) 6 634 
samples with RUNX1 or RUNX1 and CEBPA (1 to 6), and (vii) 3 samples with 2 CEBPA 635 
mutations (#1 to 3). To define mutation-specific subsets of specific DHSs, we identified 636 
peaks where the average log2 value both was at least 64 and at least 3-fold higher than in 637 
PBSCs. Downregulated DHSs are defined as being at least 3-fold less than in PBSCs. 638 
Samples were not included in these 7 specific groups in cases where, for example, 2 copies 639 
of the FLT3-ITD mutation were present, the NPM1 mutation was paired with a NRAS instead 640 
of the FLT3-ITD, RUNX1 mutations were paired with a JAK2 mutation, or where only a 641 
single CEBPA allele was mutated. 642 
Clustering of DNaseI-Seq data: Clustering of DNaseI-seq samples was carried out using 643 
the merged distal DHSs. The number of reads that mapped to these DHSs was counted in a 644 
400bp window centered on the DHS summit, and subsequently normalized to total sample 645 
size using DEseq2 59. Pearson correlation coefficients were then calculated for each pair of 646 
samples using the log2 of the normalized read counts, and then hierarchically clustered 647 
using Euclidean distance and complete linkage clustering of the correlation matrix in R. 648 
K-mean clustering of AML specific DHSs: A combined set of up-regulated distal DHSs 649 
that defined as being at least 3-fold greater than in PBSCs was used to perform 650 
unsupervised k-mean clustering. The number of reads that mapped to these peaks was 651 
counted in a 400bp window centered on the DHS summit, and subsequently normalized to 652 
total sample size using DEseq259. Clustering was done on rows (DHSs) while samples 653 
(columns) were ranked based on the hierarchical clustering in Figure 1C. Initially the read 654 
counts output from DEseq2 59 was further quartile normalised using the “preprocessCore” 655 
package in R, The log2 of the normalised reads were clustered using k-means clustering 656 
with Euclidean distances (stats package in R) and the optimal number of clusters was 657 
determined to be 20 based on the lowest Bayesian Information Criterion (BIC) scores 658 
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(Schwarz, 1978). Each of the 20 clusters was then hierarchically clustered using the 659 
“complete linkage” agglomeration method. 660 
ATAC sequencing data analysis 661 
ATAC-seq profiles of hematopoietic and leukemic cell types taken 25 were downloaded from 662 
GEO with accession number GSE74912. ATAC-seq data of HSC, MPP, CMP, CLP, MEP, 663 
GMP and Monocytes were downloaded and aligned to the human genome version hg38. 664 
Aligned reads with the same cell line were merged and then ATAC peaks were obtained 665 
using MACS2 with default parameter. Overlaps between DHS and ATAC peaks were 666 
defined by requiring the summits of two peaks to lie within +/-200 bp.  Pair-wise peak 667 
overlaps between DHSs and ATAC peaks of hematopoietic i and j were performed in order 668 
to calculate the fraction (ܯ௜௝)  669 
ܯ௜௝ = ே೔ೕே೔    where Nij is the total peaks that overlap, Ni is the total number peaks in set i 670 
(DHSs) and Nj is the total peaks in j (ATAC).  A matrix with the calculated fraction multiply by 671 
100 was generated and a heatmap was plotted (Figure 2B) after hieratically clustered in R. 672 
Clustering of DNaseI-seq and ATAC-seq samples (Figure S2A and Figure S3B) was carried 673 
out using the merged distal DHSs as described earlier using the DNaseI-seq only. 674 
ChIP sequencing data analysis 675 
ChIP-Seq sequencing reads were downloaded from GEO with accession numbers 676 
(GSM1581788, GSM1693378, GSM1466000)24 (GSM722705, GSM722704)30, the reads 677 
were aligned to the human genome version hg38 with Bowtie version 2.3.157. Reads that 678 
mapped uniquely to the genome were retained and duplicated reads were removed using 679 
the MarkDuplicates function in Picard tools (http://broadinstitute.github.io/picard/). Peaks 680 
were identified with MACS version 1.4.2 58 and DFilter software60 with recommended 681 
parameters (-bs=100 -ks=50 –refine).  Peaks common to both peak calling methods were 682 
considered for further analysis.  683 
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H3K27Ac ChIP data analysis 684 
H3K27Ac ChIP data from26 were downloaded from NCBI with accession number 685 
SRP103200. The raw reads were aligned to the human reference genome hg38 and density 686 
profiles were generated using bedtools. The bedGraph files were used to generate the 687 
H3K27Ac average coverage plotted a long side the DHSs of the 20 clusters (Figure S3D).   688 
Digital genomic footprinting 689 
Digital genomic footprinting was performed using the Wellington_footprints function of the 690 
Wellington algorithm29 on High-depth AML and CD34+ PBSC DHSs. DHS footprints 691 
probability and DNase forward and reverse cut coverages, were generated using the 692 
dnase_wig_tracks function of Wellington. AML-specific footprints compared to PBSC CD34+ 693 
cells were identified using wellington_bootstrap function of Wellington. Mutation-specific 694 
footprints of the groups were identified by using the Wellington_footprints function using the 695 
merged reads of the Mutation-specific individual DNaseI-Seq of each group. 696 
Motif identification  697 
De novo motif analysis was performed on peaks using HOMER61. Motif lengths of 6, 8, 10, 698 
and 12 bp were identified in within ± 200 bp from the peak summit. The annotatePeaks 699 
function in HOMER was used to find occurrences of motifs in peaks. In this case we used 700 
known motif position weight matrices (PWM).  701 
Motif co-localisation clustering: Motif co-localisation clustering was performed as 702 
previously described22. A motif position search was done within DHSs that are group 703 
mutation-specifically footprinted. The distance between the centres of each motif pairs was 704 
calculated and the motif frequency was counted if the first motif was within 50bps distance 705 
from the second motif. Z-scores were calculated from the mean and standard deviation of 706 
motif frequencies observed in random sets using bootstrap analysis, peak sets with a 707 
population equal to that of the footprinted peaks were randomly obtained from the merged 708 
footprints of all AML and CD34+ footprints sets. Motif search and motif frequencies 709 
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calculations were repeated 1000 times for each random set. A matrix was generated and Z-710 
scores were displayed after hierarchical clustering as a heatmap with R.  711 
Motif enrichment  712 
To identify motifs that are relatively enriched in the distal footprinted DHSs of each of AML 713 
mutation groups (Figure S5) and the AML DHSs clusters (Figure 3A). For a given set j of 714 
footprints, we defined a motif enrichment score (ESij) for motif i in footprint set j as 715 
ܧܵ௜௝ = ௡೔ೕ ெೕ⁄∑ ௡೔ೕೕ ∑ ெೕೕ⁄    where nij is the number of footprints in each subset j (j=1,2,…,12)  716 
containing motif i (i=1, 2,….,I), I is the total number of motifs used in the test, and Mj the total 717 
number of peaks in each subset j (j=1,2,…,30).  A matrix was generated and the motif 718 
enrichment scores were displayed as a heatmap after hierarchical clustering with Euclidean 719 
distance and complete linkage. The heatmap was generated using R. The statistical 720 
significance for a ESij score of a given motif i in peak set j is computed as Z-scores using 721 
bootstrapping (N=1000), where a random set of peaks is extracted from a global set of 722 
footprinted regions and ES is calculated. After N iterations the mean (μij) and the standard 723 
deviation (σij) are computed and the z-scores are computed as ܼ௜௝ = ாௌ೔ೕ ି ఓ೔ೕఙ೔ೕ . The global set 724 
of regions is a merged set of all the AML footprints. These Z-scores are provided in Table 725 
S7. 726 
RNA-seq data analysis 727 
RNA-Seq reads were aligned to the human genome hg38 build with STAR62 using ENCODE 728 
recommend parameters. Separate density profiles for the positive and negative strand were 729 
generated using bedtools. Cufflinks63 was used to calculate the expression values as 730 
Fragments Per Kilobase per Million aligned reads (FPKM) from the aligned RNA-seq data. 731 
Mutation-specific group’s gene-wise expression values were obtained using the cuffdiff 732 
function of cufflinks. The correlation between any two AML samples was obtained as the 733 
Pearson correlation coefficient of expression values over all genes. A correlation matrix was 734 
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thus generated for all the samples and hierarchically clustered to study the relationship 735 
among samples as given in Figure S1C. Smooth scatter plots were generated in R. 736 
Gene expression analysis 737 
Differentially expressed genes were extracted using the limma R package64. Genes were 738 
said to be differentially expressed (DE) if there was a twofold change in expression between 739 
any each of the AML patient sample or each of the mutation-specific group and the PBSC 740 
CD34+ with a p-value less than or equal to 0.01 and with FPKM greater than 1 in at least 741 
one AML sample. For each value of a DE gene a pseudo-count ߛ = 0.1 was added to the 742 
FPKM values and the binary logarithm of this value was considered as the expression value 743 
of the gene in each sample (j), ݁௜௝  = ݈݋݃ଶ൫ܨܲܭܯ௜௝ + ߛ൯ . These DE values were then 744 
clustered (Figure S1A) using hierarchical clustering with Euclidean distances (stats package 745 
in R).  While Hierarchical clustering of transcription factors gene expression was carried out 746 
on fold-changes for genes associated with at least a 2-fold change compared to the CD34+. 747 
Gene set enrichment analysis 748 
A publically available RNA-seq data of hematopoietic cell types were downloaded from GEO 749 
with accession number GSE74246. The downloaded RNA-seq data were processed in 750 
similar way as described above. The GSEA software65 was used to perform gene set 751 
enrichment analysis on group of genes.  Module map66 implemented by Genomic software 752 
was used to find which groups of genes are significantly up- or down-regulated using a 753 
statistical test based on the hyper-geometric distribution the fraction of up or down regulated 754 
is displayed as a heatmap (Fig 2C and Fig S4C). 755 
Gene ontology (GO) analysis: Gene ontology (GO) analysis was performed using clueGO 756 
tools65 with Hypergeometric for overrepresentation and Benjamini and Hochberg (FDR) 757 
correction for multiple testing corrections. KEGG Pathway network analysis was performed 758 
using clueGO tools65 with kappa score = 0.3. A right-sided enrichment (depletion) test based 759 
on the hypergeometric distribution was used for terms and groups. The size of the nodes 760 
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reflects the number of genes within the term. The color of nodes reflects the enrichment 761 
significance of the terms. The network is laid out using Cytoscape. The KEGG pathway 762 
network figures for all DHS-cluster associated genes are shown in Table S6.  763 
Expression profiles from larger patient cohort datasets 764 
Microarray data from Verhaak et al.42 were downloaded from GEO under the accession 765 
number GSE6891. Patients were split according to their mutational status; Boxplots showing 766 
the expression of the indicated genes in FLT3-ITD, NPM1, CEBPA, t(8;21), inv(16) and 767 
NRAS mutation groups. The statistical significance of the difference in expression between 768 
FLT3-ITD and other mutations was determined using an unpaired t-test. 769 
Promoter Capture HiC data analysis 770 
The CHi-C paired-end sequencing reads from ITD/NMP1-2 and t(8;21)-1R patients and a 771 
publically available CD34+ dataset (accession numbers ERR436032 and ERR436025)  were 772 
put through HiCUP pipeline67. The raw sequencing reads were separated and mapped 773 
against the human genome (hg38). The reads were then filtered for experimental artefacts 774 
and duplicate reads, and then re-paired. Statistically significant interactions were called 775 
using GOTHiC package68 and HOMER software. This uses a cumulative binomial test to 776 
detect interactions between distal genomic loci that have significantly more reads than 777 
expected by chance, by using a background model of random interactions. This analysis 778 
assigns each interaction with a p-value, which represents its significance. Differential 779 
interactions were determined with HOMER61 for t(8;21) using FLT3-ITD or CD34+ as 780 
background and FLT3-ITD using t(8;21) or CD34+ as a background. A difference with a p-781 
value of less than 0.1 was deemed to be significant 782 
Transcription Factor Gene Regulatory Network Construction 783 
We identified a subset of 310 transcription factor (TF) genes that are expressed in one or 784 
more of our AML samples. The gene names for transcription factors in human were obtained 785 
from AnimalTFDB69. The 310 TFs were considered as nodes and the nodes coloured 786 
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according to their expression values at each AML subtype (Fig 6, Fig S9 and Fig SN5). 787 
Node border colour signifies whether the gene is up-regulated, down-regulated or invariant 788 
base on a 2-fold-change compared to CD34+ cells. Node border type indicates whether 789 
gene is differentially expressed in one AML subtype as compared to other subtypes. A 790 
directed edge from TFa to TFb indicates motif binding of a TFa to the locus of the TFb and the 791 
edge is prominently displayed if TFa binds to the locus at that stage. The edge is classified 792 
and colour coded according to the significant of motif count enrichment.  793 
Motif count enrichment for TFs network: Initially footprints for each AML subtype were 794 
identified by using the Wellington algorithm29 and were annotated to their related promoter 795 
using CHi-C data where possible. Motif search within footprint coordinates where performed 796 
using HOMER61.  The number of motifs per TF gene were counted and the significance of 797 
motif enrichment was identified using bootstrapping on random sampling, a random set of 798 
mapped motif were extracted from all union footprinted motif of all AML subtypes and the 799 
CD34+ cells. After 1000 iterations the mean, standard deviation and the z-scores are 800 
computed. Motif (TFa) is linked to gene (TFb) with only positive Z-score.  801 
Motif count enrichment for up-regulated TFs: The correlations (re) between all TF genes 802 
based on FPKM values from the RNA-seq analysis were identified and the correlations (rm) 803 
between all TF genes based on motif count binding were identified. The correlation 804 
coefficients were z-transformed using Fisher Z-transformation with “FisherZ” function in R.  805 
The average of the transformed z-scores of both gene expression and motif were 806 
transformed to correlation (r). All TF genes with a correlation coefficient equal or greater 807 
than a cut-off of 0.3 were considered. Then for each AML cell type, the differentially 808 
expressed TF genes among these correlated genes were identified. First with AML subtype 809 
as compared to CD34+ cells and second with AML subtype compared to the average 810 
expression of other subtypes includes the CD34+.  Up-regulated genes with a 2-fold-change 811 
in expression were either compared to CD34+ or compared to other AMLs were considered 812 
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to construct the network. Motif enrichment for the correlated and up-regulated TF genes and 813 
edges were identified as described above. 814 
List of used position weight matrices: A description of how the motifs were curated can 815 
be found in the legend of Table S2. 816 
 817 
Data availability 818 
Processed data will be available from our webserver  819 
http://bioinformatics-bham.co.uk/tfinaml/ 820 
Password sal2018.  821 
Raw data have been deposited at GEO under the accession number GSE108316.  822 
 823 
References 824 
1. Cancer Genome Atlas Research, N. Genomic and epigenomic landscapes of adult 825 
de novo acute myeloid leukemia. N Engl J Med 368, 2059-74 (2013). 826 
2. Papaemmanuil, E. et al. Genomic Classification and Prognosis in Acute Myeloid 827 
Leukemia. New England Journal of Medicine 374, 2209-2221 (2016). 828 
3. Bonifer, C. & Cockerill, P.N. Chromatin Structure Profiling Identifies Crucial 829 
Regulators of Tumor Maintenance. Trends Cancer 1, 157-160 (2015). 830 
4. Rosenbauer, F. & Tenen, D.G. Transcription factors in myeloid development: 831 
balancing differentiation with transformation. Nature reviews. Immunology 7, 105-17 832 
(2007). 833 
5. Cockerill, P.N. Receptor Signaling Directs Global Recruitment of Pre-existing 834 
Transcription Factors to Inducible Elements. Yale J Biol Med 89, 591-596 (2016). 835 
6. Ward, A.F., Braun, B.S. & Shannon, K.M. Targeting oncogenic Ras signaling in 836 
hematologic malignancies. Blood 120, 3397-406 (2012). 837 
 34
7. Parikh, C., Subrahmanyam, R. & Ren, R. Oncogenic NRAS rapidly and efficiently 838 
induces CMML- and AML-like diseases in mice. Blood 108, 2349-57 (2006). 839 
8. Masson, K. & Ronnstrand, L. Oncogenic signaling from the hematopoietic growth 840 
factor receptors c-Kit and Flt3. Cell Signal 21, 1717-26 (2009). 841 
9. Gerloff, D. et al. NF-kappaB/STAT5/miR-155 network targets PU.1 in FLT3-ITD-842 
driven acute myeloid leukemia. Leukemia 29, 535-47 (2015). 843 
10. Corces-Zimmerman, M.R., Hong, W.J., Weissman, I.L., Medeiros, B.C. & Majeti, R. 844 
Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators 845 
and persist in remission. Proc Natl Acad Sci U S A 111, 2548-53 (2014). 846 
11. Shlush, L.I. et al. Identification of pre-leukaemic haematopoietic stem cells in acute 847 
leukaemia. Nature 506, 328-33 (2014). 848 
12. Di Croce, L. & Helin, K. Transcriptional regulation by Polycomb group proteins. 849 
Nature structural & molecular biology 20, 1147-55 (2013). 850 
13. Broske, A.M. et al. DNA methylation protects hematopoietic stem cell multipotency 851 
from myeloerythroid restriction. Nature genetics 41, 1207-15 (2009). 852 
14. Bonifer, C. & Bowen, D.T. Epigenetic mechanisms regulating normal and malignant 853 
haematopoiesis: new therapeutic targets for clinical medicine. Expert reviews in 854 
molecular medicine 12, e6 (2010). 855 
15. Challen, G.A. et al. Dnmt3a is essential for hematopoietic stem cell differentiation. 856 
Nature genetics 44, 23-31 (2012). 857 
16. Ko, M. et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with 858 
mutant TET2. Nature 468, 839-43 (2010). 859 
17. Shih, A.H., Abdel-Wahab, O., Patel, J.P. & Levine, R.L. The role of mutations in 860 
epigenetic regulators in myeloid malignancies. Nature reviews. Cancer 12, 599-612 861 
(2012). 862 
 35
18. Goode, D.K. et al. Dynamic Gene Regulatory Networks Drive Hematopoietic 863 
Specification and Differentiation. Dev Cell 36, 572-87 (2016). 864 
19. Obier, N. & Bonifer, C. Chromatin programming by developmentally regulated 865 
transcription factors: lessons from the study of haematopoietic stem cell specification 866 
and differentiation. FEBS Lett 590, 4105-4115 (2016). 867 
20. Wilson, N.K. et al. Combinatorial transcriptional control in blood stem/progenitor 868 
cells: genome-wide analysis of ten major transcriptional regulators. Cell Stem Cell 7, 869 
532-44 (2010). 870 
21. Rubin, A.J. et al. Lineage-specific dynamic and pre-established enhancer-promoter 871 
contacts cooperate in terminal differentiation. Nat Genet 49, 1522-1528 (2017). 872 
22. Ptasinska, A. et al. Identification of a Dynamic Core Transcriptional Network in 873 
t(8;21) AML that Regulates Differentiation Block and Self-Renewal. Cell Reports 8, 874 
1974-1988 (2014). 875 
23. Loke, J. et al. RUNX1-ETO and RUNX1-EVI1 Differentially Reprogram the 876 
Chromatin Landscape in t(8;21) and t(3;21) AML. Cell Rep 19, 1654-1668 (2017). 877 
24. Cauchy, P. et al. Chronic FLT3-ITD Signaling in Acute Myeloid Leukemia Is 878 
Connected to a Specific Chromatin Signature. Cell Rep 12, 821-36 (2015). 879 
25. Corces, M.R. et al. Lineage-specific and single-cell chromatin accessibility charts 880 
human hematopoiesis and leukemia evolution. Nat Genet 48, 1193-203 (2016). 881 
26. McKeown, M.R. et al. Superenhancer Analysis Defines Novel Epigenomic Subtypes 882 
of Non-APL AML, Including an RARalpha Dependency Targetable by SY-1425, a 883 
Potent and Selective RARalpha Agonist. Cancer Discov 7, 1136-1153 (2017). 884 
27. Martens, J.H. et al. ERG and FLI1 binding sites demarcate targets for aberrant 885 
epigenetic regulation by AML1-ETO in acute myeloid leukemia. Blood 120, 4038-48 886 
(2012). 887 
 36
28. Pulikkan, J.A., Tenen, D.G. & Behre, G. C/EBPalpha deregulation as a paradigm for 888 
leukemogenesis. Leukemia 31, 2279-2285 (2017). 889 
29. Piper, J. et al. Wellington: a novel method for the accurate identification of digital 890 
genomic footprints from DNase-seq data. Nucleic Acids Res 41, e201 (2013). 891 
30. Ptasinska, A. et al. Depletion of RUNX1/ETO in t(8;21) AML cells leads to genome-892 
wide changes in chromatin structure and transcription factor binding. Leukemia 26, 893 
1829-1841 (2012). 894 
31. Mandoli, A. et al. CBFB-MYH11/RUNX1 together with a compendium of 895 
hematopoietic regulators, chromatin modifiers and basal transcription factors 896 
occupies self-renewal genes in inv(16) acute myeloid leukemia. Leukemia 28, 770-8 897 
(2014). 898 
32. Dunne, J. et al. AML1/ETO proteins control POU4F1/BRN3A expression and function 899 
in t(8;21) acute myeloid leukemia. Cancer Res 70, 3985-95 (2010). 900 
33. Dekker, J., Rippe, K., Dekker, M. & Kleckner, N. Capturing chromosome 901 
conformation. Science 295, 1306-11 (2002). 902 
34. Mifsud, B. et al. Mapping long-range promoter contacts in human cells with high-903 
resolution capture Hi-C. Nat Genet 47, 598-606 (2015). 904 
35. Chasman, D. & Roy, S. Inference of cell type specific regulatory networks on 905 
mammalian lineages. Curr Opin Syst Biol 2, 130-139 (2017). 906 
36. Neph, S. et al. Circuitry and dynamics of human transcription factor regulatory 907 
networks. Cell 150, 1274-86 (2012). 908 
37. Lin, S. et al. A FOXO1-induced oncogenic network defines the AML1-ETO 909 
preleukemic program. Blood 130, 1213-1222 (2017). 910 
38. O'Connor, C. et al. Nfix expression critically modulates early B lymphopoiesis and 911 
myelopoiesis. PLoS One 10, e0120102 (2015). 912 
 37
39. Somerville, T.D. et al. Frequent Derepression of the Mesenchymal Transcription 913 
Factor Gene FOXC1 in Acute Myeloid Leukemia. Cancer Cell 28, 329-42 (2015). 914 
40. Olive, M. et al. A dominant negative to activation protein-1 (AP1) that abolishes DNA 915 
binding and inhibits oncogenesis. J Biol Chem 272, 18586-94 (1997). 916 
41. Obier, N. et al. Cooperative binding of AP-1 and TEAD4 modulates the balance 917 
between vascular smooth muscle and hemogenic cell fate. Development 143, 4324-918 
4340 (2016). 919 
42. Verhaak, R.G.W. et al. Prediction of molecular subtypes in acute myeloid leukemia 920 
based on gene expression profiling. Haematologica 94, 131-134 (2009). 921 
43. Figueroa, M.E. et al. DNA Methylation Signatures Identify Biologically Distinct 922 
Subtypes in Acute Myeloid Leukemia. Cancer cell 17, 13-27 (2010). 923 
44. Lin, S., Mulloy, J.C. & Goyama, S. RUNX1-ETO Leukemia. Adv Exp Med Biol 962, 924 
151-173 (2017). 925 
45. Goyama, S. et al. UBASH3B/Sts-1-CBL axis regulates myeloid proliferation in human 926 
preleukemia induced by AML1-ETO. Leukemia 30, 728-39 (2016). 927 
46. Sun, X.J. et al. A stable transcription factor complex nucleated by oligomeric AML1-928 
ETO controls leukaemogenesis. Nature 500, 93-7 (2013). 929 
47. Essig, A., Duque-Afonso, J., Schwemmers, S., Pahl, H.L. & Lubbert, M. The 930 
AML1/ETO target gene LAT2 interferes with differentiation of normal hematopoietic 931 
precursor cells. Leuk Res 38, 340-5 (2014). 932 
48. Trop-Steinberg, S. & Azar, Y. AP-1 Expression and its Clinical Relevance in Immune 933 
Disorders and Cancer. Am J Med Sci 353, 474-483 (2017). 934 
49. Kesarwani, M. et al. Targeting c-FOS and DUSP1 abrogates intrinsic resistance to 935 
tyrosine-kinase inhibitor therapy in BCR-ABL-induced leukemia. Nat Med 23, 472-936 
482 (2017). 937 
 38
50. Faber, Z.J. et al. The genomic landscape of core-binding factor acute myeloid 938 
leukemias. Nat Genet 48, 1551-1556 (2016). 939 
51. Levis, M. et al. Results from a randomized trial of salvage chemotherapy followed by 940 
lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood 117, 3294-301 941 
(2011). 942 
52. DePristo, M.A. et al. A framework for variation discovery and genotyping using next-943 
generation DNA sequencing data. Nat Genet 43, 491-8 (2011). 944 
53. van Gosliga, D. et al. Establishing long-term cultures with self-renewing acute 945 
myeloid leukemia stem/progenitor cells. Exp Hematol 35, 1538-49 (2007). 946 
54. Weber, K., Bartsch, U., Stocking, C. & Fehse, B. A multicolor panel of novel lentiviral 947 
"gene ontology" (LeGO) vectors for functional gene analysis. Mol Ther 16, 698-706 948 
(2008). 949 
55. Mostoslavsky, G. et al. Efficiency of transduction of highly purified murine 950 
hematopoietic stem cells by lentiviral and oncoretroviral vectors under conditions of 951 
minimal in vitro manipulation. Mol Ther 11, 932-40 (2005). 952 
56. Bert, A.G., Johnson, B.V., Baxter, E.W. & Cockerill, P.N. A modular enhancer is 953 
differentially regulated by GATA and NFAT elements that direct different tissue-954 
specific patterns of nucleosome positioning and inducible chromatin remodeling. Mol 955 
Cell Biol 27, 2870-85 (2007). 956 
57. Langmead, B. & Salzberg, S.L. Fast gapped-read alignment with Bowtie 2. Nat 957 
Methods 9, 357-9 (2012). 958 
58. Zhang, Y. et al. Model-based analysis of ChIP-Seq (MACS). Genome Biol 9, R137 959 
(2008). 960 
59. Love, M.I., Huber, W. & Anders, S. Moderated estimation of fold change and 961 
dispersion for RNA-seq data with DESeq2. Genome Biol 15, 550 (2014). 962 
 39
60. Kumar, V. et al. Uniform, optimal signal processing of mapped deep-sequencing 963 
data. Nat Biotechnol 31, 615-22 (2013). 964 
61. Heinz, S. et al. Simple Combinations of Lineage-Determining Transcription Factors 965 
Prime cis-Regulatory Elements Required for Macrophage and B Cell Identities. 966 
Molecular Cell 38, 576-589 (2010). 967 
62. Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15-21 968 
(2013). 969 
63. Trapnell, C. et al. Differential analysis of gene regulation at transcript resolution with 970 
RNA-seq. Nat Biotechnol 31, 46-53 (2013). 971 
64. Ritchie, M.E. et al. limma powers differential expression analyses for RNA-972 
sequencing and microarray studies. Nucleic Acids Res 43, e47 (2015). 973 
65. Bindea, G. et al. ClueGO: a Cytoscape plug-in to decipher functionally grouped gene 974 
ontology and pathway annotation networks. Bioinformatics 25, 1091-3 (2009). 975 
66. Segal, E., Friedman, N., Koller, D. & Regev, A. A module map showing conditional 976 
activity of expression modules in cancer. Nat Genet 36, 1090-8 (2004). 977 
67. Wingett, S. et al. HiCUP: pipeline for mapping and processing Hi-C data. F1000Res 978 
4, 1310 (2015). 979 
68. Mifsud, B. et al. GOTHiC, a probabilistic model to resolve complex biases and to 980 
identify real interactions in Hi-C data. PLoS One 12, e0174744 (2017). 981 
69. Zhang, H.M. et al. AnimalTFDB: a comprehensive animal transcription factor 982 
database. Nucleic Acids Res 40, D144-9 (2012). 983 
 40
 984 
 985 
 986 
Acknowledgements 987 
This research was funded by a programme grant from Bloodwise (15001) to C.B. and P.N.C, 988 
as well as studentship awards from Cancer Research UK and Bloodwise to A.Pickin and 989 
N.G, respectively, a Kay Kendall Clinical Training Fellowship for J.L. and a MRC/Leuka 990 
Clinical Training Fellowship for S.P. 991 
 992 
 993 
Author Affiliations 994 
1 Institute of Cancer and Genomic Sciences, University of Birmingham, B17 2TT, UK 995 
2 Northern Institute for Cancer Research, University of Newcastle, Newcastle, UK 996 
3Section of Experimental Haematology, Leeds Institute for Molecular Medicine, University of 997 
Leeds, Leeds LS9 7TF, UK 998 
4 West Midlands Regional Genetics Laboratory, Birmingham Women’s NHS Foundation 999 
Trust, Birmingham B15 2TG, UK  1000 
5 CMT Laboratory NHS Blood & Transplant, Edgbaston, Birmingham, B15 2SG, UK 1001 
6 Department of Hematology, Erasmus University Medical Center, Dr. Molewaterplein 50, 1002 
3015 GE Rotterdam, the Netherlands 1003 
7 Haematological Malignancy Diagnostic Service, St. James’s University Hospital, Leeds LS9 1004 
7TF, UK 1005 
8 Centre for Clinical Haematology, Queen Elizabeth Hospital, Birmingham B15 2TG, UK, UK 1006 
 1007 
Author contributions: 1008 
 41
M.R.I., D.C., S.P., A.P, H.P., A. Pickin, N.G., J.L., P.S.C, R.R., S.R.J. performed 1009 
experiments and generated data, H.R.D., M.R., S.R., M.G. P.J., A.U. provided patient 1010 
samples, S.C., A,B, and P.N.C. conducted mutation analysis, S.A.A. and P.C. analysed 1011 
data, O.H. supervised transplantation experiments and helped editing the manuscript, C.B. 1012 
and P.N.C. conceived and directed the study and CB wrote the manuscript. 1013 
 1014 
Competing financial interests 1015 
The authors declare no competing financial interests. 1016 
 1017 
Corresponding authors 1018 
Constanze Bonifer (c.bonifer@bham.ac.uk) and Peter N. Cockerill 1019 
(p.n.cockerill@bham.ac.uk). 1020 
  1021 
 42
Figure Legends 1022 
 1023 
Figure 1: Different types of AML adopt unique transcriptome and chromatin 1024 
landscapes. (A) Experimental strategy. (B) UCSC Genome browser tracks of DNaseI-seq 1025 
mapping in purified AML cells. (C) Hierarchical clustering of Pearson correlation coefficients 1026 
of DNaseI accessible sequences from all patient samples with normalized read counts of 1027 
DNaseI-Seq data for the different classes of mutations (left panel), right panel: list of 1028 
mutations in cells from each patient 1029 
 1030 
 1031 
Figure 2: Different types of AML are blocked at different stages of differentiation and 1032 
are regulated by different transcriptional network. (A) Hematopoietic hierarchy; shown 1033 
are some of the precursor stages from which ATAC-seq and RNA-seq data were generated 1034 
in Corces et al., 2016: Hematopoietic stem cells (HSC), common myeloid progenitors 1035 
(CMP), common lymphoid progenitors (CLP), Megakaryocyte Erythrocyte Precursors (MEP) 1036 
and Granulocyte Macrophage Precursors (GMP). (B) Clustering of the correlation of 1037 
percentage of peak overlap between DNaseI-Seq and ATAC-seq data by first generating a 1038 
matrix with all overlap percentages between all DHS peaks, and ATAC-seq peaks and then 1039 
hierarchically clustering. (C) Gene set enrichment analysis for the differentially expressed 1040 
genes that are at least 2-fold different compared to the normal CD34+ PBSCs. Up and down 1041 
regulated gene expression patterns were tested for their similarity to specific pairs of 1042 
progenitor RNA-seq data from Corces et al. 2016, representing different steps of 1043 
differentiation. Up-regulated genes are shown in top panel and the bottom panel shows the 1044 
down-regulated genes. 1045 
 1046 
 1047 
 43
Figure 3: AML-specifically active cis-regulatory elements cluster into common and 1048 
unique chromatin landscapes. (A) Heatmap depicting unsupervised K-mean clustering of 1049 
the DNaseI-Seq log2 signals seen in each AML specific distal DHS peak in each AML 1050 
sample compared to PBSCs. Clustering was done only on rows (DHS peaks) while samples 1051 
were ranked based on the clustering in Figure 1C. A diagram on top of the heatmap shows 1052 
the DHS peak population used for clustering. (B) A binary heatmap shows the overlap 1053 
between the clusters from A and the DHSs of the 7 mutation classes which are deregulated 1054 
compared to CD34+ve PBSCs as described in Fig S4A. (C) The percentage of DHS peaks 1055 
that overlap with ATAC-Seq data from different progenitor types, DHS clusters from Figure 1056 
3A was overlapped with each of the progenitor ATAC peaks; these include CLP, CMP, 1057 
GMP, MPP, LMPP, MEP and Monocyte populations. 1058 
 1059 
Figure 4: AML-specifically active cis-regulatory elements display AML type-specific 1060 
transcription factor occupancy patterns. (A) UCSC browser screen shot of the MDFI 1061 
locus zooming in on an AML type-specific DHS (box). (B) Heatmap depicting the degree of 1062 
motif enrichment after hierarchical clustering of motif occupancy in each of the 20 AML DHS 1063 
clusters. Enrichment score was calculated by the level of motif enrichment in all the 1064 
footprints of all high read-depth samples for each cluster, as compared to union of footprints 1065 
in all experiments. (C) Enrichment analysis of motifs footprinted in AML subgroups which 1066 
overlap with ATAC-Seq peaks present in precursor cells 25. 1067 
 1068 
Figure 5: Capture HiC shows differences in locus-specific cis-regulatory interactions 1069 
between different types of AML and normal cells. (A) Heatmaps showing the raw 1070 
interactions of the promoter capture HiC data using purified patient blasts on chromosome 2 1071 
for the FLT3-ITD (FLT3-ITD/NPM1 patient) (left), t(8;21) (middle) and CD34+ (right), a 1072 
UCSC tracks is shown below each heatmap. (B) Flow diagram shows the step for 1073 
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identification of the differential interactions and the downstream analysis. (C) Percentage of 1074 
up- and down-regulated genes with differential interactions from the FLT3-ITD and the 1075 
t(8;21) compared to CD34+. The bar figure shows also the percentage of the common genes 1076 
for the FLT3-ITD and the t(8;21), the number of DEG is shown on top of each bar.  (D) Top 1077 
enriched GO terms for the up-regulated genes of the FLT3-ITD compared to the CD34+ as 1078 
outlined in (A). (E) Network diagram of top KEGG pathways for the up-regulated genes of 1079 
the FLT3-ITD compared to the CD34+ as outlined in (A). (F) Top enriched GO terms for the 1080 
up-regulated genes of the t(8;21) compared to the CD34+ shown as outlined in (A) Network 1081 
diagram of top KEGG pathways for the up-regulated genes of the t(8;21) compared to the 1082 
CD34+ as outlined in (B). (H): percentage of RUNX1-ETO and RUNX1 targets amongst up-1083 
regulated genes with differential interactions. 1084 
 1085 
Figure 6: Identification of transcription factor networks driving the expression of AML 1086 
type-specific up-regulated TF genes  1087 
(A) Outline of analysis strategy. (B) t(8;21)-specific TF network, (C) CEBPA(x2)-specific TF, 1088 
(D) INv(16) specific TF network, (E) Mutant RUNX1-specific TF network, (F) FLT3-1089 
ITD/NPM1 specific TF network, (G) NPM1-specific TF network 1090 
Factor families binding to the same motif as shown in Table S2 form a node contained within 1091 
a circle. Arrows going outwards from the entire node highlight footprinted motifs in individual 1092 
genes generated by any member of this factor family whereby the footprint was annotated to 1093 
the gene using the CHiC data where possible, otherwise to the nearest gene. For selected 1094 
nodes, the name of the underlying motif is highlighted in large grey letters. The expression 1095 
level (FKPM) for the individual genes is depicted in white (low)/red (high) colour. An orange 1096 
smooth ring around the circle indicates that this gene is specifically up-regulated in this type 1097 
of AML compared to CD34+ PBSCs and/or other AML types, a dotted circle indicates a gene 1098 
 45
that is up-regulated as compared to CD34+ cells. Genes with no outgoing arrows due to a 1099 
lack of know binding motifs are highlighted by their octagon shapes. 1100 
 1101 
7: Identification of AML type-specific TFs required for maintaining leukemic growth 1102 
and colony forming ability. 1103 
(A - C) Histogram showing the growth curves of (A) Kasumi-1 cells after transduction with 1104 
shPOU4F1 and (B) of MV4-11 cells after transduction with shNFIX. (D, E) Histogram 1105 
showing the number of colonies formed by a FLT3-ITD+ primary AML cell samples (D) or 1106 
PBSCs (E) after transduction with shRNA targeting FOXC1, NFIX or a mismatch control. (F) 1107 
Histogram showing the growth curve of Kasumi-1 cells transduced with either a doxycycline-1108 
inducible dominant negative FOS or an empty vector control (right panel) with and without 1109 
1.5 mcg/ml doxycycline. (G) Histogram showing the growth curve of MV4-11 cells 1110 
transduced with either a doxycycline-inducible dominant negative FOS or an empty vector 1111 
control (right panel) with and without 1.5 μg/ml doxycycline. (H,I) The expression of a 1112 
dominant negative FOS causes a reduction in the colony forming ability of CD34+ FLT3-ITD+ 1113 
primary AML cells (H) but not CD34+ PBSCs (I). All experiments were performed in triplicate 1114 
(n=3) with * p<0.05, **p<0.01. Error bars show 95% confidence intervals. (J) (J) 1115 
Granulosarcoma formation in RG mice by Kasumi-1 expressing a doxycycline-inducible 1116 
dnFOS. dnFOS was induced by intraperitoneal injection of doxycycline. (K) Survival curve 1117 
for RG mice transplanted with MV4-11 cells expressing doxycycline-inducible dnFOS. 1118 
dnFOS was induced by adding doxycycline to the drinking water. The control group did not 1119 
develop any tumors during the observed time frame while all mice of the induced group had 1120 
to be sacrificed.  1121 
  1122 
 1123 
 1124 
Patient code Signalling NPM1 Chrom RUNX Other mutations
RUNX1-T/JAK-2 JAK2 RUNX1 TET2x2,TP53
RUNX1-D/JAK-1 JAK2 tri(21,9) RUNX1 IDH2, SRSF2
RUNX1-D-5 RUNX1 IDH1, BCORL1x2, SRSF2x2
RUNX1-T/CEBPA-6 NRAS tri(8) RUNX1 CEBPA, EZH2
RUNX1(x2)-D&T-4 RUNX1x2 DNMT3A, IDH2, SRSF2
RUNX1-DT-3 RUNX1
RUNX1-DT/CEBPA-2 FLT3-ITD RUNX1 CEBPA, WT1x2, SF3B1, TP53
RUNX1-DT-1 FLT3 tri(13) RUNX1 CREBBP, DNMT3A, SF3B1 
PBSC-1
PBSC-2
inv(3)/RAS-1 NRAS inv(3) GATA2, SF3B1
inv(3)/CBL-2 CBL inv(3) SF3B1
ITD/NPM1-4 FLT3-ITD NPM1 GATA2, DNMT3A
ITD-1 FLT3-ITD DNMT3A, TET2x2, BCOR, TP53
ITD/NPM1-5 FLT3-ITD NPM1 DNMT3A, BCOR
ITD-3 FLT3-ITD DNMT3A
ITD/NPM1-6 FLT3-ITD NPM1 WT1, DNMT3A, TET2, PHF6
ITD-2 FLT3-ITD tri(13) DNMT3A, TET2
ITD/NPM1-1 FLT3-ITD NPM1 WT1, DNMT3A 
ITD/NPM1-3 FLT3-ITD NPM1
ITD/NPM1-2 FLT3-ITD NPM1
NPM1-1 NPM1 IDH1
NPM1-2 NPM1 DNMT3A, TET2x2
ITD(2x)/NPM1-2 FLT3-ITDx2 NPM1 CEBPA, IDH2
ITD(2x)/NPM1-1 FLT3-ITDx2 NPM1 DNMT3A, IDH2
CEBPA(x2)-3 CEBPAx2, GATA2, TET2
CEBPA(x2)-2 CEBPAx2, GATA2
CEBPA(x2)-1 CEBPAx2
t(8;21)-1 t(8;21) TET2
t(8;21)-1R KIT t(8;21) TET2
t(8;21)-3 FLT3-TK t(8;21)
t(8;21)/KIT-2 KIT t(8;21) NOTCH1
t(8;21)-4 t(8;21)
inv(16)-3 inv(16) ASXL1
inv(16)-2 inv(16)
inv(16)-1 KIT inv(16)
RUNX1-T-7 (NHL) tri(21) RUNX1 TET2x2, PHF6
NPM1/RAS-3 NRAS NPM1 PTPN11, DNMT3A, IDH1
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Long terminal repeat (LTR) elements are wide-spread in the human genome and have the
30 potential to act as promoters and enhancers. Their expression is therefore under tight
31 epigenetic control. We previously reported in classical Hodgkin Lymphoma (cHL) that a
32 member of the THE1B class of LTR elements acted as a promoter for the proto-oncogene
33 and growth factor receptor gene CSF1R and that expression of this gene is required for
34 cHL tumour survival. However, to which extent and how such elements participate in
35 globally shaping the unique cHL gene expression program is unknown. To address this
36 question we mapped the genome-wide activation of THE1-LTRs in cHL cells using a
37 targeted next generation sequencing approach (RACE-Seq). Integration of these data with
38 global gene expression data from cHL and control B cell lines showed a unique pattern of
39 LTR activation impacting on gene expression, including genes associated with the cHL
40 phenotype. We also show that global LTR activation is induced by strong inflammatory
41 stimuli. Together these results demonstrate that LTR activation provides an additional layer
42 of gene deregulation in classical Hodgkin lymphoma and highlight the potential impact of
43 genome-wide LTR activation in other inflammatory diseases.
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Supplemental Materials 
 
 
1. Supplemental Figures and Tables  
 
 
 
Supplemental Table 1: Patient groups, mutation data, and clinical data. Patient codes 
depicted in color represent samples included in the seven major defined mutation groups, or which 
have either 2 FLT-ITD mutations or a mutation in either CBL or NRAS. This table also indicates 
samples where DHS-Seq and RNA-Seq data is either available (Y) or not available (N). Further 
details can be found in Supplemental data-set 1. 
  
patient code Signalling NPM1 Chrom RUNX Other mutations DHSSeq
RNA
Seq Age Sex wbc case
ITD-1 FLT3-ITD DNMT3A, TET2x2, BCOR, TP53 Y Y 45 F 56 Rel
ITD-2 FLT3-ITD tri(13) DNMT3A, TET2 Y Y 68 F 2 Pres
ITD-3 FLT3-ITD DNMT3A Y Y 80 F 143 Pres
ITD/NMP1-1 FLT3-ITD NPM1 DNMT3A, WT1 Y Y 45 F 32 Pres
ITD/NPM1-2 FLT3-ITD NPM1 Y Y 61 F 7 Rel
ITD/NPM1-3 FLT3-ITD NPM1 Y Y 66 F 91 Pres
ITD/NPM1-4 FLT3-ITD NPM1 GATA2, DNMT3A Y Y 65 F 21 Pres
ITD/NPM1-5 FLT3-ITD NPM1 DNMT3A, BCOR Y Y 68 M 190 Pres
ITD/NPM1-6 FLT3-ITD NPM1 WT1, DNMT3A, TET2, PHF6 Y Y 58 F 195 Pres
NPM1-1 NPM1 IDH1 Y Y 37 M 60 Pres
NPM1-2 NPM1 DNMT3A, TET2x2 Y Y 75 M 94 Pres
t(8;21)-1 t(8;21) TET2 Y Y 72 M 29 Pres
t(8;21)/KIT-2 KIT t(8;21) NOTCH1 Y Y 48 M 36 Pres
t(8;21)-3 FLT3-TK t(8;21) Y Y 53 M 6 Pres
t(8;21)-4 t(8;21) Y Y 45 M 2 Pres
inv(16)-1 KIT inv(16) Y Y 40 M 22 Pres
inv(16)-2 inv(16) Y Y 26 M 63 Pres
inv(16)-3 inv(16) ASXL1 Y Y 75 M 54 Pres
RUNX1-DT-1 FLT3 tri(13) RUNX1 CREBBP, DNMT3A, SF3B1 Y Y 68 M 112 Rel
RUNX1-DT/CEBPA-2 FLT3-ITD RUNX1 CEBPA, WT1x2, SF3B1, TP53 Y Y 83 M 68 Pres
RUNX1-DT-3 RUNX1 Y Y 58 M 37 Pres
RUNX1(x2)-D&T-4 RUNX1x2 SRSF2, DNMT3A, IDH2 Y Y 82 M 55 Pres
RUNX1-D-5 RUNX1 IDH1, BCORL1x2, SRSF2x2 Y Y 65 M 8 Pres
RUNX1-T/CEBPA-6 NRAS tri (8) RUNX1 CEBPA, EZH2 Y Y 75 M 107 Pres
CEBPA(x2)-1 CEBPAx2 Y Y 76 F 238 Pres
CEBPA(x2)-2 CEBPAx2, GATA2 Y Y 21 F 10 Pres
CEBPA(x2)-3 CEBPAx2, GATA2, TET2 Y Y 75 M 106 Pres
ITD(2x)/NPM1-1 FLT3-ITDx2 NPM1 DNMT3A, IDH2 Y Y 78 F 26 Pres
ITD(2x(/NPM1-2 FLT3-ITDx2 NPM1 CEBPA, IDH2 Y Y 72 F 68 Pres
NPM1/RAS-3 NRAS NPM1 PTPN11, DNMT3A, IDH1 Y Y 30 F 4 Rel
inv(3)/RAS-3 NRAS inv(3) ETV6, SF3B1 N Y 54 M 104 Pres
inv(3)/RAS-1 NRAS inv(3) GATA2, SF3B1 Y Y 59 M 4 Rel
inv(3)/CBL-2 CBL inv(3) SF3B1 Y N 34 F 21 Rel
t(8;21)/ITD(x2)-5 FLT3-ITD t(8;21) SMC1A N Y 43 M 86 Pres
RUNX1-D/JAK-1 JAK2 tri (21, 9) RUNX1 IDH2, SRSF2 Y Y 79 M 12 Pres
RUNX1-T/JAK-2 JAK2 RUNX1 TET2x2, TP53 Y Y 77 F 79 Pres
RUNX1-T-7 (NHL) tri (21) RUNX1 TET2x2, PHF6 Y Y 73 F NA Pres
CEBPA-5 CEBPA, DNMT3A N Y 79 F 40 Pres
SRSF2-1 IDH2, SRSF2 N Y 67 M 2 Pres
SRSF2-2 SOCS1, DNMT3A, IDH2, SRSF2 N Y 71 M 2 Pres
t(8;21)-1R KIT t(8;21) TET2 Y Y 72 M 29 Rel
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Supplemental Table 2 
 
§    
motif logo motif logo motif logo
AHR HSF1 PRDM1
AP-1 IKZF PU.1
AR IRF RAR
BCL6 IRX REST
CAMTA KLF RFX
C/EBP LEF1 RUNX
CREB/ATF MAF RXR
CTCF MYC/MAX SMAD
CUT MEF2 SNAI
E2F MEIS SOX
EGR MITF SP
ESR1 MNX1 SRF
ESRRA MYB ST18
ETS NF1 STAT3
ETS:E-box NFAT STAT5
EVI NFE2 STAT6
FOXO NFIL3 TAL1
FOX:E-box NF-kB TCF3
GATA NFY TEAD
GFI1B NKX TFCP2
GLI NR TFDP1
HBP1 NRF1 TGIF
HES OCT THR
HHEX PAX5 VDR
HIC1 PBX VENTX
HIF1A PKNOX1 XBP1
HINFP POU4F1
HOX PPAR
List of used Position Weight Matrices
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Supplemental Table 2: List of representative position weight matrices for TF families. 
 
To improve the process of linking regulatory factors with their binding sites on DNA, we 
consolidated the different versions of transcription factor consensus binding sequences for closely 
related family members where the motif signatures are indistinguishable. For most transcription 
factor families there are typically various alternate subtly different versions of position weight 
matrices for not just different family members but also for the same factor from different data sets. 
The prevalence of so many different related consensus sequences is a major impediment to the 
construction of regulatory networks from genome-wide analyses of DNA elements. For the current 
study, we first identified a subset of almost 300 transcription factor genes that are expressed in 
one or more of our AML samples. We then inspected the motifs listed on either the HOMER or 
JASPER databases, motifs defined in a recent large-scale study of recombinant proteins (Jolma et 
al 2013, 10.1016/j.cell.2012.12.009), or motifs described in various other publications. We grouped 
together those factors where the motifs are essentially the same, and chose the best 
representative example for further analysis. These selections were often validated by referring to 
the large body of literature which is devoted to defining specific motifs, which also informed the 
choices of which orientation of motifs represented the conventional form used in publications. The 
JASPAR motifs were viewed via http://jaspar.genereg.net/. The HOMER motifs were viewed 
via http://homer.ucsd.edu/homer/motif/HomerMotifDB/homerResults.html. 
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Supplemental Figure 1: Different types of AML adopt unique transcriptomes. (A) Hierarchical 
clustering of gene expression as determined by RNA-Seq of all patient samples. Clustering of log2 
FPKM values for all differentially expressed genes changing expression at least 2 fold in at least 
one patient as compared to normal CD34+ PBSC. (B) UCSC genome browser screenshots of 
DNaseI-Seq in all AML patients with different classes of mutations and normal CD34+ PBSC at 
POU4F1 (left panel) and FOXC1 (right panel) locus. (C) Hierarchical clustering of Pearson 
correlation coefficient between all patient samples of RNA-Seq data: (left panel), right panel: list of 
mutations in cells from each patient. The correlation between any two patients was obtained with 
log2 FPKM expression values over all genes. (D) UCSC genome browser screenshots of RNA-
Seq reads in AML patients at POU4F1 (left panel) and FOXC1 (right panel) locus. Asterisks denote 
samples for which the matching RNA-Seq or DNaseI-Seq data are unavailable.  
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Supplemental Figure 2: Different types of AML adopt unique transcriptome and 
chromatinlandscapes. (A) Hierarchical clustering of Pearson correlation coefficients of DNaseI 
Up-regulated transcriptional regulator genes
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	 6	
accessible sequences from all our patient samples with normalized read counts of DNase-Seq 
data for the different classes of mutations also including ATAC-Seq data from Corces et al., 2016 
with similar mutations (SU(nnn), mostly FLT3-ITD). The mutation class is highlighted to the right of 
the panel and by a color code below the heatmap, again showing that specific elements from 
specific AML-types cluster together. Note the tight clustering of FLT3 and RAS mutant AML. (B) 
Scatter plots comparing the DNaseI tag count signals of patients with (11) and without (8) DNMT3 
mutations against each other and against PBSCs as indicated by colored shapes. (C) Smooth 
scatter plots showing the correlation between DNase-Seq and RNA-Seq data from AML patients. 
Shown are CD34+ PBSC cells from individual  #1 versus individual #2 (left plot), CD34+ PBSC 
from individual #2 versus a patient with NPM1 and NRAS mutation (right plot). RNA-Seq plots (top 
panel) and DNaseI-Seq plots (bottom panel). Other comparisons can be retrieved from the 
webserver. (D) Hierarchical clustering of log2 gene expression fold difference for all differentially 
transcription factor (TFs) and transcriptional regulator genes changing expression at least 2 fold in 
at least one patient as compared to normal CD34+ PBSC. Clustering was done only on rows (i.e., 
genes) while samples were ranked based on the clustering in Figure 1C. The heatmap colour is 
related to the degree of differential expression (fold-change (FC)). Red is up-regulated compared 
to normal CD34+ and blue is a down regulated TF. 
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Supplementary Figure 3
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Gene set enrichment analysis for up-regulated genes 
DNA-Seq and ATAC 
correlation clustering
H3K27Ac within AML DHS groups (McKeown et al. 2017)
	 8	
Supplemental Figure 3: Different types of AML are blocked at different stages of 
differentiation and correlation with publicly available data-sets. (A) Smooth scatter plots show 
the correlation between AML DNase-Seq and ATAC-Seq data. Top panel shows the DNAseI-Seq 
from normal CD34+ PBSC patient #1 & #2 versus the ATAC-Seq from Hematopoietic stem cells 
(HSC) and lower panel shows the DNaseI-Seq from normal CD34+ PBSC patient #1 & #2 versus 
the ATAC-Seq from Monocytes (Mono). (B) Hierarchical clustering of Pearson correlation 
coefficient between all patient samples of AML-Seq data plus the ATAC-seq data from Corces et 
al. The correlation between any two patients was obtained with normalized read counts calculated 
with +/- 200 bases from the peak center. (C) Gene set enrichment analysis for the up-regulated 
genes that are at least 2 fold difference compared to the normal CD34+. The AML up-regulated 
genes were tested for enrichment against the common myeloid progenitors (CMP) versus 
Granulocyte Macrophage Precursors (GMP) taken from Corces et al RNA-seq data. (D) Heatmap 
showing density enrichment of H3K27Ac peaks from McKeown et al., 2017 ranked according to 
the same coordinates of the DNase-Seq within the clusters (left heatmap), the H3K27Ac densities 
were plotted with a window size of +/- 2 kb around the DNaseI-Seq peaks summit. Selected AML-
specific blocks of peaks are highlighted. The asterisk highlights samples inv(3)/CBL-2 for which 
RNA-Seq is available. 
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Supplemental Figure 4: AML-specifically active cis-regulatory elements cluster into 
common and unique chromatin landscapes and correlate with the upregulation of 
expression of the nearest genes. (A) Venn diagrams depicting the overlaps of subsets of DHSs 
which are up regulated compared to CD34+ve PBSCs within each of 7 mutation classes. These 
groups were generated as the average log2 values for 7 distinct subsets of AMLs that carried the 
same specific mutations in key regulators. These 7 mutation groups are defined on the basis of 
average values derived from 3 ITD patients, 6 ITD/NPM1 patients, 2 NPM1 patients, 4 t(8;21) 
patients, 3 inv(16) patients, 6 RUNX1 patients, and 3 patients with 2 CEBPA mutations. These 
groups are defined in Table S1 (note colour code). Up-regulated DHSs are defined as being at 
least 3-fold greater than in PBSCs, and have a DHS signal spanning a 400 bp window of at least 
64. (B De novo motif search results using Homer for the up regulated DHSs classes and in 
overlapping deregulated DHSs for ITD and/or NPM1 and for CEBPA and RUNX1 that are shown in 
(A) the numbers indicate of percentage of each subset that contains the identified motif. (C) Gene 
set enrichment analysis for all expressed genes that are annotated to the DHSs identified in each 
of the AML specific 20 clusters, the enrichment scores (right panel) are aligned against each of the 
20 clusters (left panel) that was initially described in Figure 3A. The target genes were tested for 
enrichment against all AML RNA-seq data; red color indicates that these genes are enriched with 
up-regulated genes compared to CD34+ PBSC. (D) Correlation of gene expression with DNaseI 
tag count as exemplified for the POU4F1 gene (see also S1 B,D). (E) Bar figures depicting the 
expression level for some of the targets differentially expressed genes, the FPKM values were 
plotted on the y-axis for each AML samples used in this study, the color code identified each of the 
mutation classes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 11	
 
 
Supplemental Figure 5: Common and group-specific DHS associate with genes belonging 
to different functional groups. Boxplots validating gene expression patterns for some of the 
differentially expressed genes genes using gene expression data from Verhaak et al (2009).  P-
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values highlighting the significance of differences are shown on each panel; the t-test was used to 
calculate the p-values.  
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Supplemental Figure 6: AML-specifically active cis-regulatory elements are characterized 
by specific transcription factor binding patterns. (A) Percentage of the footprints in the AML 
specific DHSs for the 20 clusters identified in Figure 3A.  The footprints were identified using the 
Wellington algorithm. We first identified differential footprints for each AML sample compared to 
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the CD34+ PBSCs and then the percentage of these differential footprints in the DHS subsets in 
the 20 clusters was calculated. (B) UCSC genome browser screenshot of DNAseI-Seq data 
aligned with digital footprints at the C3AE1 locus. The screenshot shows the DHSs for one patient 
from each group. Footprint probabilities as calculated by Wellington (Piper et al., 2015) are 
indicated as grey density below the lines. The bottom indicates the precise location of occupied 
RUNX, C/EBP and AP-1 footprints. (C) Percentage of footprints with RUNX motifs in the indicated 
AML-types peaks which are bound by RUNX1 or RUNX1-ETO in ChIP assays from 22,33,66. (D) 
Heatmap depicting the degree of motif enrichment after hierarchical clustering of all (not just the 
specific) motif enrichments for each of the mutation-specific AML groups. Enrichment scores were 
calculated by the level of motif enrichment in all the footprints of all Hi-read depth samples for each 
group, as compared to the union of footprints in all experiments.  
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Supplemental Figure 7: Capture HiC shows differences in cis-regulatory interactions 
between different types of AML and normal cells. (A) Smooth scatter plots show the correlation 
	 16	
between t(8;21)-1 presentation and t(8;21)-1 relapse AML DNAseI-Seq data. (B) Heatmaps show 
the raw overall inter and intra interactions of the promoter capture HiC data for all chromosomes 
for FLT3-ITD (ITD/NPM1-2, left), t(8;21) (middle) and CD34+ (right) across all chromosomes. (C) 
Bar figure showing the percentage of DHSs within each of the 20 clusters identified in Figure 3A 
that have differential interactions compared to CD34+, (D, E) percentage of DHSs within each of 
the 20 clusters interacting with the nearest gene within differential interactions for all genes 
expressed genes as identified by the RNA-Seq data. D: FLT3-ITD and E: t(8;21). (F) Heatmap of 
differential interactions ranked by the strength of interaction (-log p-value) from highly significant to 
less for the FLT3-ITD and from less significant to more significant for the t(8;21) (left panel) Plotted 
along-side are  the gene expression fold-difference for the FLT3-ITD compared to the t(8;21) and 
for the FLT3-ITD (middle panel) and the DHS fold difference FLT3-ITD versus the t(8;21) (right 
panel). (F) The top enriched GO terms for the up regulated genes in the FLT3-ITD compared the 
t(8;21) where the DHSs differentially interact with the promoter of that gene. Similarly the bottom 
panel the top enriched GO terms for the up regulated genes in the t(8;21) compared to the FLT3-
ITD such that the DHS is differentially interact with the promoter of that gene.. (G) UCSC genome 
browser showing a screenshot of KLF2. The top two tracks display the log p-value of the capture 
HiC interaction for KLF2 promoter as viewpoint, the following two tracks display log p-value of the 
differential interaction of the t(8;21) and the FLT3-ITD compared to the CD34+. Shown are also the 
DNaseI-Seq and RNA-Seq data of t(8;21), FLT3-ITD and CD34+ PBSC.  (H) Bar diagram showing 
the percentage of DHSs involved in significant interactions. (I) Bar diagram showing the 
percentage of DHSs involved in significant differential interactions compared to CD34+ cells. (J) 
Bar diagram showing the percentage of DHSs involved in significant differential interactions for 
DHSs unique to FLT3-ITD or t(8;21) DHSs compared to CD34+ cells, with DHS common to FLT3-
ITD and t(8;21) being excluded. (K) Enriched footprinted motifs in DHS associated each of the 20 
clusters involved in differential interactions for the two patients. Motifs for transcription factors 
normally not expressed in myeloid cells are highlighted in yellow, motifs for inducible factors are 
marked in green.  
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Supplemental Figure 8: Interactions are representative for their patient groups and the 
majority of interactions are shared (A)  
(A) Percentage of all DHSs with interactions present in each dataset of each individual patients, 
(B) Heat-map highlighting the percentage of AML-type specific DHS with interactions found in the 
different patient groups, indicating that the patient chosen for the Chi-C experiment are 
representative for each patient group. (C) Percentage of up-regulated gens associated with DHS 
clusters that have significant interactions in any of the three Chi-C experiments. (D) Overlap of all 
DHSs underlying interactions in all three samples as indicated demonstrating that the majority of 
interactions are the same in all three samples.  
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Supplemental Figure 9: Identification of transcription factor network components driving 
the expression of TF genes in each AML subtype which are shared with CD34+ cells.  Here 
we projected the links from the indicated AML subtypes onto the CD34+ footprints. Top panels: 
Analysis strategy. (A) Shared t(8;21) TF network, (B) Shared CEBPA(x2) TF, (C) Shared Inv(16) 
TF network, (D) Shared Mutant RUNX1 TF network, E) Shared FLT3-ITD/NPM1 TF network, (F) 
Shared NPM1- TF network. Factor families binding to the same motif as shown in Table S2 form a 
	 19	
node contained within a circle. Arrows going outwards from the entire node highlight footprinted 
motifs in individual genes generated by any member of this factor family whereby the footprint was 
annotated to the gene using the Chi-C data where possible, otherwise to the nearest gene. The 
expression level (FKPM) for the individual genes is depicted in white (low)/red (high) colour. An 
orange smooth ring around the circle indicates that this gene is specifically up-regulated in this 
type of AML compared to CD34+ PBSCs and/or other AML types, a dotted circle indicates a gene 
that is up-regulated as compared to CD34+ cells. Genes with no outgoing arrows due to a lack of 
know binding motifs are highlighted by an octagon shape. For a detailed guide to node and edge 
attributes: See legend of Figure 6. 
	 20	 
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Supplemental Figure 10 
AML type-specifically expressed transcription factors are required for leukemic growth. (A, 
B, C) Histograms showing POU4F1 (A), FOXC1 (B) and NFIX  (C) mRNA expression after 
transduction with the indicated shRNA and control lentiviruses in Kasumi-1, MV4-11 and Fujijoka 
cell lines, respectively. Note that Fujijoka cells express high levels of FOXC1 and were only used 
to test the functionality of our lentiviral construct. FOXC1 is not highly expressed in MV4-11 cells. 
(D-F) Western Blots showing the efficiencies of shRNA knock-down for FOXC1 (D), NFIX (E) and 
POU4F1 (F).  (G - I) Histogram showing doubling time of t(8;21) Kasumi-1 cells after transduction 
with shPOU4F1 (G), MV4-11 cells after transduction with shNFIX (H) and  of Kasumi-1 cells after 
transduction with shNFIX (I).  (J, K): doubling times of Kasumi-1 (J) and MV4-11 cells (K) 
expressing a DOX inducible version of a dominant negative FOS peptide (dnFOS) (K,M) as well as 
empty control virus (L,O). All experiments were performed in triplicate. In all histograms n=3 * 
p<0.05, **p<0.01, ***p<0.001. Error bars show 95% confidence intervals. (L) Pictures of 
representative colonies derived from FLT3-ITD patient cells and CD34+ PBSCs transduced with 
the indicated lentiviral vectors. 
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List of supplemental data files 
 
Dataset S1: Summary of all AML mutation data 
Dataset S2: Up and down-regulated genes associated with mutation groups (related to Figure 3 
and Figure S4B) 
Dataset S3: Number of differentially expressed genes for Figure 2C and Figure S4C 
Dataset S4:  List of transcriptional regulator genes showing AML type-specific expression (related 
to Figure S2C) 
Dataset S5: Gene lists and GO terms for Figure 5 and Figure S7F. 
Dataset S6: CHi-C-curated KEGG pathways and GO terms of DHS-cluster associated genes 
(related to Figure 3) 
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